#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-8	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
1-2	9-12	and	_
1-3	13-20	cocaine	_
1-4	21-29	decrease	_
1-5	30-39	cognitive	_
1-6	40-47	impulse	_
1-7	48-55	control	_
1-8	56-59	and	_
1-9	60-70	functional	_
1-10	71-86	corticostriatal	_
1-11	87-99	connectivity	_
1-12	100-102	in	_
1-13	103-107	drug	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-14	108-113	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-15	114-118	with	_
1-16	119-122	low	_
1-17	123-131	activity	_
1-18	132-135	DBH	_
1-19	136-145	genotypes	_
1-20	146-149	The	_
1-21	150-158	dopamine	_
1-22	159-172	β-hydroxylase	_
1-23	173-174	(	_
1-24	175-178	DβH	_
1-25	179-180	)	_
1-26	181-187	enzyme	_
1-27	188-198	transforms	_
1-28	199-207	dopamine	_
1-29	208-212	into	_
1-30	213-226	noradrenaline	_
1-31	227-228	.	_

2-1	229-231	We	_
2-2	232-244	hypothesized	_
2-3	245-249	that	_
2-4	250-261	individuals	_
2-5	262-266	with	_
2-6	267-270	low	_
2-7	271-279	activity	_
2-8	280-283	DBH	_
2-9	284-293	genotypes	_
2-10	294-295	(	_
2-11	296-305	rs1611115	_
2-12	306-311	CT/TT	_
2-13	312-313	)	_
2-14	314-317	are	_
2-15	318-322	more	_
2-16	323-332	sensitive	_
2-17	333-335	to	_
2-18	336-339	the	_
2-19	340-349	influence	_
2-20	350-352	of	_
2-21	353-361	cannabis	_
2-22	362-365	and	_
2-23	366-373	cocaine	_
2-24	374-376	on	_
2-25	377-386	cognitive	_
2-26	387-394	impulse	_
2-27	395-402	control	_
2-28	403-406	and	_
2-29	407-417	functional	_
2-30	418-430	connectivity	_
2-31	431-433	in	_
2-32	434-437	the	_
2-33	438-444	limbic	_
2-34	445-446	‘	_
2-35	447-453	reward	_
2-36	454-455	’	_
2-37	456-463	circuit	_
2-38	464-471	because	_
2-39	472-476	they	_
2-40	477-487	experience	_
2-41	488-489	a	_
2-42	490-494	drug	_
2-43	495-502	induced	_
2-44	503-520	hyperdopaminergic	_
2-45	521-526	state	_
2-46	527-535	compared	_
2-47	536-538	to	_
2-48	539-550	individuals	_
2-49	551-555	with	_
2-50	556-560	high	_
2-51	561-569	activity	_
2-52	570-573	DBH	_
2-53	574-583	genotypes	_
2-54	584-585	(	_
2-55	586-595	rs1611115	_
2-56	596-598	CC	_
2-57	599-600	)	_
2-58	601-602	.	_

3-1	603-610	Regular	_
3-2	611-615	drug	_
3-3	616-621	users	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
3-4	622-623	(	_
3-5	624-625	N	_
3-6	626-627	=	_
3-7	628-631	122	_
3-8	632-633	)	_
3-9	634-642	received	_
3-10	643-648	acute	_
3-11	649-654	doses	_
3-12	655-657	of	_
3-13	658-666	cannabis	_
3-14	667-668	(	_
3-15	669-672	450	_
3-16	673-678	μg/kg	_
3-17	679-682	THC	_
3-18	683-684	)	_
3-19	685-686	,	_
3-20	687-694	cocaine	_
3-21	695-698	HCl	_
3-22	699-702	300	_
3-23	703-705	mg	_
3-24	706-709	and	_
3-25	710-717	placebo	_
3-26	718-719	.	_

4-1	720-729	Cognitive	_
4-2	730-737	impulse	_
4-3	738-745	control	_
4-4	746-749	was	_
4-5	750-758	assessed	_
4-6	759-761	by	_
4-7	762-767	means	_
4-8	768-770	of	_
4-9	771-774	the	_
4-10	775-783	Matching	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
4-11	784-792	Familiar	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
4-12	793-800	Figures	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
4-13	801-805	Test	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
4-14	806-807	(	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
4-15	808-812	MFFT	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
4-16	813-814	)	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
4-17	815-816	.	_

5-1	817-824	Resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-2	825-830	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-3	831-835	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-4	836-839	was	_
5-5	840-848	measured	_
5-6	849-851	in	_
5-7	852-853	a	_
5-8	854-860	subset	_
5-9	861-863	of	_
5-10	864-876	participants	_
5-11	877-879	to	_
5-12	880-889	determine	_
5-13	890-900	functional	_
5-14	901-913	connectivity	_
5-15	914-921	between	_
5-16	922-925	the	_
5-17	926-933	nucleus	_
5-18	934-943	accumbens	_
5-19	944-945	(	_
5-20	946-949	NAc	_
5-21	950-951	)	_
5-22	952-955	and	_
5-23	956-957	(	_
5-24	958-961	sub	_
5-25	962-963	)	_
5-26	964-972	cortical	_
5-27	973-978	areas	_
5-28	979-980	.	_

6-1	981-984	The	_
6-2	985-994	influence	_
6-3	995-997	of	_
6-4	998-1006	cannabis	_
6-5	1007-1010	and	_
6-6	1011-1018	cocaine	_
6-7	1019-1021	on	_
6-8	1022-1033	impulsivity	_
6-9	1034-1037	and	_
6-10	1038-1048	functional	_
6-11	1049-1061	connectivity	_
6-12	1062-1075	significantly	_
6-13	1076-1086	interacted	_
6-14	1087-1091	with	_
6-15	1092-1095	DBH	_
6-16	1096-1104	genotype	_
6-17	1105-1106	.	_

7-1	1107-1111	Both	_
7-2	1112-1117	drugs	_
7-3	1118-1127	increased	_
7-4	1128-1137	cognitive	_
7-5	1138-1149	impulsivity	_
7-6	1150-1152	in	_
7-7	1153-1165	participants	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
7-8	1166-1170	with	http://maven.renci.org/NeuroBridge/neurobridge#SubjectwithoutDisorder
7-9	1171-1176	CT/TT	http://maven.renci.org/NeuroBridge/neurobridge#Pheochromocytoma
7-10	1177-1186	genotypes	http://maven.renci.org/NeuroBridge/neurobridge#Pheochromocytoma
7-11	1187-1190	but	_
7-12	1191-1194	not	_
7-13	1195-1197	in	_
7-14	1198-1200	CC	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
7-15	1201-1213	participants	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
7-16	1214-1215	.	_

8-1	1216-1220	Both	_
8-2	1221-1226	drugs	_
8-3	1227-1231	also	_
8-4	1232-1239	reduced	_
8-5	1240-1250	functional	_
8-6	1251-1263	connectivity	_
8-7	1264-1271	between	_
8-8	1272-1275	the	_
8-9	1276-1279	NAc	_
8-10	1280-1283	and	_
8-11	1284-1287	the	_
8-12	1288-1294	limbic	_
8-13	1295-1299	lobe	_
8-14	1300-1301	,	_
8-15	1302-1312	prefrontal	_
8-16	1313-1319	cortex	_
8-17	1320-1321	,	_
8-18	1322-1330	striatum	_
8-19	1331-1334	and	_
8-20	1335-1343	thalamus	_
8-21	1344-1347	and	_
8-22	1348-1357	primarily	_
8-23	1358-1360	in	_
8-24	1361-1372	individuals	_
8-25	1373-1377	with	_
8-26	1378-1383	CT/TT	http://maven.renci.org/NeuroBridge/neurobridge#Pheochromocytoma
8-27	1384-1393	genotypes	_
8-28	1394-1395	.	_

9-1	1396-1409	Correlational	_
9-2	1410-1418	analysis	_
9-3	1419-1428	indicated	_
9-4	1429-1430	a	_
9-5	1431-1442	significant	_
9-6	1443-1451	negative	_
9-7	1452-1463	association	_
9-8	1464-1471	between	_
9-9	1472-1481	cognitive	_
9-10	1482-1493	impulsivity	_
9-11	1494-1497	and	_
9-12	1498-1508	functional	_
9-13	1509-1521	connectivity	_
9-14	1522-1524	in	_
9-15	1525-1536	subcortical	_
9-16	1537-1542	areas	_
9-17	1543-1545	of	_
9-18	1546-1549	the	_
9-19	1550-1555	brain	_
9-20	1556-1557	.	_

10-1	1558-1560	It	_
10-2	1561-1563	is	_
10-3	1564-1573	concluded	_
10-4	1574-1578	that	_
10-5	1579-1591	interference	_
10-6	1592-1594	of	_
10-7	1595-1603	cannabis	_
10-8	1604-1607	and	_
10-9	1608-1615	cocaine	_
10-10	1616-1620	with	_
10-11	1621-1630	cognitive	_
10-12	1631-1638	impulse	_
10-13	1639-1646	control	_
10-14	1647-1650	and	_
10-15	1651-1661	functional	_
10-16	1662-1677	corticostriatal	_
10-17	1678-1690	connectivity	_
10-18	1691-1698	depends	_
10-19	1699-1701	on	_
10-20	1702-1705	DBH	_
10-21	1706-1714	genotype	_
10-22	1715-1716	.	_

11-1	1717-1720	The	_
11-2	1721-1728	present	_
11-3	1729-1733	data	_
11-4	1734-1741	provide	_
11-5	1742-1743	a	_
11-6	1744-1750	neural	_
11-7	1751-1760	substrate	_
11-8	1761-1764	and	_
11-9	1765-1775	behavioral	_
11-10	1776-1785	mechanism	_
11-11	1786-1788	by	_
11-12	1789-1794	which	_
11-13	1795-1799	drug	_
11-14	1800-1805	users	_
11-15	1806-1809	can	_
11-16	1810-1818	progress	_
11-17	1819-1821	to	_
11-18	1822-1826	drug	_
11-19	1827-1834	seeking	_
11-20	1835-1838	and	_
11-21	1839-1842	may	_
11-22	1843-1847	also	_
11-23	1848-1853	offer	_
11-24	1854-1855	a	_
11-25	1856-1865	rationale	_
11-26	1866-1869	for	_
11-27	1870-1878	targeted	_
11-28	1879-1894	pharmacotherapy	_
11-29	1895-1897	in	_
11-30	1898-1905	chronic	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
11-31	1906-1910	drug	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
11-32	1911-1916	users	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
11-33	1917-1921	with	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
11-34	1922-1926	high	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
11-35	1927-1931	risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
11-36	1932-1935	DBH	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
11-37	1936-1945	genotypes	_
11-38	1946-1947	.	_

12-1	1948-1955	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
12-2	1956-1968	Participants	_
12-3	1969-1981	Participants	_
12-4	1982-1986	were	_
12-5	1987-1996	recruited	_
12-6	1997-1999	at	_
12-7	2000-2001	2	_
12-8	2002-2007	study	_
12-9	2008-2013	sites	_
12-10	2014-2015	(	_
12-11	2016-2019	i.e	_
12-12	2020-2021	.	_

13-1	2022-2032	Maastricht	_
13-2	2033-2036	and	_
13-3	2037-2045	Nijmegen	_
13-4	2046-2047	)	_
13-5	2048-2052	that	_
13-6	2053-2065	participated	_
13-7	2066-2068	in	_
13-8	2069-2073	this	_
13-9	2074-2085	multicenter	_
13-10	2086-2091	trial	_
13-11	2092-2093	.	_

14-1	2094-2096	In	_
14-2	2097-2102	total	_
14-3	2103-2104	,	_
14-4	2105-2108	122	_
14-5	2109-2116	regular	_
14-6	2117-2122	users	_
14-7	2123-2125	of	_
14-8	2126-2134	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
14-9	2135-2138	and	_
14-10	2139-2146	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
14-11	2147-2148	(	_
14-12	2149-2153	male	_
14-13	2154-2155	N	_
14-14	2156-2157	=	_
14-15	2158-2160	96	_
14-16	2161-2162	,	_
14-17	2163-2169	female	_
14-18	2170-2171	N	_
14-19	2172-2173	=	_
14-20	2174-2176	26	_
14-21	2177-2178	)	_
14-22	2179-2186	entered	_
14-23	2187-2190	the	_
14-24	2191-2196	study	_
14-25	2197-2198	.	_

15-1	2199-2201	On	_
15-2	2202-2209	average	_
15-3	2210-2211	,	_
15-4	2212-2224	participants	_
15-5	2225-2228	had	_
15-6	2229-2233	been	_
15-7	2234-2241	regular	_
15-8	2242-2247	users	_
15-9	2248-2250	of	_
15-10	2251-2259	cannabis	_
15-11	2260-2263	and	_
15-12	2264-2271	cocaine	_
15-13	2272-2275	for	_
15-14	2276-2277	7	_
15-15	2278-2281	yrs	_
15-16	2282-2283	.	_

16-1	2284-2285	(	_
16-2	2286-2293	min-max	_
16-3	2294-2295	:	_
16-4	2296-2300	1–23	_
16-5	2301-2302	)	_
16-6	2303-2306	and	_
16-7	2307-2310	3.2	_
16-8	2311-2314	yrs	_
16-9	2315-2316	.	_

17-1	2317-2318	(	_
17-2	2319-2332	min-max:0.5–6	_
17-3	2333-2334	)	_
17-4	2335-2347	respectively	_
17-5	2348-2349	.	_

18-1	2350-2362	Participants	_
18-2	2363-2371	reported	_
18-3	2372-2374	an	_
18-4	2375-2382	average	_
18-5	2383-2384	(	_
18-6	2385-2387	SD	_
18-7	2388-2389	;	_
18-8	2390-2397	min-max	_
18-9	2398-2399	)	_
18-10	2400-2403	use	_
18-11	2404-2406	of	_
18-12	2407-2415	cannabis	_
18-13	2416-2419	and	_
18-14	2420-2427	cocaine	_
18-15	2428-2430	on	_
18-16	2431-2435	44.8	_
18-17	2436-2437	(	_
18-18	2438-2442	26.8	_
18-19	2443-2444	)	_
18-20	2445-2448	and	_
18-21	2449-2452	3.7	_
18-22	2453-2454	(	_
18-23	2455-2458	3.5	_
18-24	2459-2460	)	_
18-25	2461-2470	occasions	_
18-26	2471-2483	respectively	_
18-27	2484-2490	during	_
18-28	2491-2494	the	_
18-29	2495-2503	previous	_
18-30	2504-2505	3	_
18-31	2506-2512	months	_
18-32	2513-2514	.	_

19-1	2515-2527	Participants	_
19-2	2528-2532	also	_
19-3	2533-2541	reported	_
19-4	2542-2545	the	_
19-5	2546-2549	use	_
19-6	2550-2552	of	_
19-7	2553-2558	other	_
19-8	2559-2569	substances	_
19-9	2570-2574	such	_
19-10	2575-2577	as	_
19-11	2578-2582	MDMA	_
19-12	2583-2584	(	_
19-13	2585-2587	88	_
19-14	2588-2589	%	_
19-15	2590-2591	)	_
19-16	2592-2593	,	_
19-17	2594-2606	amphetamines	_
19-18	2607-2608	(	_
19-19	2609-2611	73	_
19-20	2612-2613	%	_
19-21	2614-2615	)	_
19-22	2616-2617	,	_
19-23	2618-2627	mushrooms	_
19-24	2628-2629	(	_
19-25	2630-2632	61	_
19-26	2633-2634	%	_
19-27	2635-2636	)	_
19-28	2637-2638	,	_
19-29	2639-2642	LSD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
19-30	2643-2644	(	_
19-31	2645-2647	20	_
19-32	2648-2649	%	_
19-33	2650-2651	)	_
19-34	2652-2655	and	_
19-35	2656-2657	a	_
19-36	2658-2663	range	_
19-37	2664-2666	of	_
19-38	2667-2680	miscellaneous	_
19-39	2681-2686	drugs	_
19-40	2687-2688	(	_
19-41	2689-2691	60	_
19-42	2692-2693	%	_
19-43	2694-2695	)	_
19-44	2696-2700	such	_
19-45	2701-2703	as	_
19-46	2704-2711	nitrous	_
19-47	2712-2717	oxide	_
19-48	2718-2719	,	_
19-49	2720-2724	MDMA	_
19-50	2725-2733	crystals	_
19-51	2734-2735	,	_
19-52	2736-2739	DMT	_
19-53	2740-2743	and	_
19-54	2744-2752	ketamine	_
19-55	2753-2754	.	_

20-1	2755-2759	Mean	_
20-2	2760-2761	(	_
20-3	2762-2764	SD	_
20-4	2765-2766	)	_
20-5	2767-2770	age	_
20-6	2771-2773	of	_
20-7	2774-2786	participants	_
20-8	2787-2790	was	_
20-9	2791-2795	22.8	_
20-10	2796-2797	(	_
20-11	2798-2801	3.7	_
20-12	2802-2803	)	_
20-13	2804-2807	yrs	_
20-14	2808-2809	.	_

21-1	2810-2814	Mean	_
21-2	2815-2816	(	http://maven.renci.org/NeuroBridge/neurobridge#Thing
21-3	2817-2819	SD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
21-4	2820-2821	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
21-5	2822-2827	trait	_
21-6	2828-2839	impulsivity	_
21-7	2840-2845	score	_
21-8	2846-2848	as	_
21-9	2849-2857	assessed	_
21-10	2858-2862	with	_
21-11	2863-2866	the	_
21-12	2867-2874	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
21-13	2875-2888	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
21-14	2889-2894	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
21-15	2895-2898	was	_
21-16	2899-2903	69.5	_
21-17	2904-2905	(	_
21-18	2906-2909	9.6	_
21-19	2910-2911	)	_
21-20	2912-2913	.	_

22-1	2914-2926	Participants	_
22-2	2927-2931	were	_
22-3	2932-2941	recruited	_
22-4	2942-2949	through	_
22-5	2950-2964	advertisements	_
22-6	2965-2967	in	_
22-7	2968-2973	local	_
22-8	2974-2984	newspapers	_
22-9	2985-2986	,	_
22-10	2987-2993	flyers	_
22-11	2994-3005	distributed	_
22-12	3006-3008	at	_
22-13	3009-3017	targeted	_
22-14	3018-3027	locations	_
22-15	3028-3029	(	_
22-16	3030-3034	e.g.	_
22-17	3035-3036	,	_
22-18	3037-3044	college	_
22-19	3045-3053	campuses	_
22-20	3054-3055	,	_
22-21	3056-3060	bars	_
22-22	3061-3062	,	_
22-23	3063-3068	night	_
22-24	3069-3074	clubs	_
22-25	3075-3076	,	_
22-26	3077-3085	concerts	_
22-27	3086-3087	,	_
22-28	3088-3092	head	_
22-29	3093-3098	shops	_
22-30	3099-3100	)	_
22-31	3101-3104	and	_
22-32	3105-3107	by	_
22-33	3108-3112	word	_
22-34	3113-3115	of	_
22-35	3116-3121	mouth	_
22-36	3122-3123	.	_

23-1	3124-3134	Candidates	_
23-2	3135-3143	received	_
23-3	3144-3145	a	_
23-4	3146-3153	medical	_
23-5	3154-3165	examination	_
23-6	3166-3168	by	_
23-7	3169-3172	the	_
23-8	3173-3180	medical	_
23-9	3181-3192	supervisors	_
23-10	3193-3196	who	_
23-11	3197-3207	determined	_
23-12	3208-3213	study	_
23-13	3214-3225	eligibility	_
23-14	3226-3227	.	_

24-1	3228-3231	The	_
24-2	3232-3239	medical	_
24-3	3240-3250	supervisor	_
24-4	3251-3258	checked	_
24-5	3259-3264	vital	_
24-6	3265-3270	signs	_
24-7	3271-3272	,	_
24-8	3273-3282	conducted	_
24-9	3283-3284	a	_
24-10	3285-3292	resting	_
24-11	3293-3300	12-lead	_
24-12	3301-3318	electrocardiogram	http://maven.renci.org/NeuroBridge/neurobridge#Electrocardiograph
24-13	3319-3320	(	http://maven.renci.org/NeuroBridge/neurobridge#Electrocardiograph
24-14	3321-3324	ECG	http://maven.renci.org/NeuroBridge/neurobridge#Electrocardiograph
24-15	3325-3326	)	http://maven.renci.org/NeuroBridge/neurobridge#Electrocardiograph
24-16	3327-3328	,	_
24-17	3329-3333	took	_
24-18	3334-3339	blood	_
24-19	3340-3343	and	_
24-20	3344-3349	urine	_
24-21	3350-3357	samples	_
24-22	3358-3359	.	_

25-1	3360-3372	Participants	_
25-2	3373-3379	filled	_
25-3	3380-3383	out	_
25-4	3384-3385	a	_
25-5	3386-3394	standard	_
25-6	3395-3408	questionnaire	_
25-7	3409-3411	on	_
25-8	3412-3419	medical	_
25-9	3420-3427	history	_
25-10	3428-3429	.	_

26-1	3430-3438	Standard	_
26-2	3439-3444	blood	_
26-3	3445-3454	chemistry	_
26-4	3455-3456	,	_
26-5	3457-3467	hematology	_
26-6	3468-3469	,	_
26-7	3470-3473	DBH	_
26-8	3474-3484	genotyping	_
26-9	3485-3488	and	_
26-10	3489-3493	drug	_
26-11	3494-3500	screen	_
26-12	3501-3506	tests	_
26-13	3507-3511	were	_
26-14	3512-3521	conducted	_
26-15	3522-3524	on	_
26-16	3525-3530	blood	_
26-17	3531-3534	and	_
26-18	3535-3540	urine	_
26-19	3541-3548	samples	_
26-20	3549-3561	respectively	_
26-21	3562-3563	.	_

27-1	3564-3573	Inclusion	_
27-2	3574-3582	criteria	_
27-3	3583-3587	were	_
27-4	3588-3589	:	_
27-5	3590-3597	written	_
27-6	3598-3606	informed	_
27-7	3607-3614	consent	_
27-8	3615-3616	;	_
27-9	3617-3620	age	_
27-10	3621-3626	18–40	_
27-11	3627-3630	yrs	_
27-12	3631-3632	.	_

28-1	3633-3634	;	_
28-2	3635-3636	(	_
28-3	3637-3644	regular	_
28-4	3645-3646	)	_
28-5	3647-3650	use	_
28-6	3651-3653	of	_
28-7	3654-3662	cannabis	_
28-8	3663-3664	(	_
28-9	3665-3668	i.e	_
28-10	3669-3670	.	_

29-1	3671-3672	≥	_
29-2	3673-3674	2	_
29-3	3675-3682	times/3	_
29-4	3683-3685	mo	_
29-5	3686-3687	)	_
29-6	3688-3689	;	_
29-7	3690-3697	cocaine	_
29-8	3698-3701	use	_
29-9	3702-3704	at	_
29-10	3705-3710	least	_
29-11	3711-3712	5	_
29-12	3713-3718	times	_
29-13	3719-3721	in	_
29-14	3722-3725	the	_
29-15	3726-3734	previous	_
29-16	3735-3739	year	_
29-17	3740-3741	,	_
29-18	3742-3746	good	_
29-19	3747-3755	physical	_
29-20	3756-3759	and	_
29-21	3760-3766	mental	_
29-22	3767-3773	health	_
29-23	3774-3777	and	_
29-24	3778-3784	normal	_
29-25	3785-3791	weight	_
29-26	3792-3793	(	_
29-27	3794-3797	BMI	_
29-28	3798-3803	18-28	_
29-29	3804-3805	)	_
29-30	3806-3807	.	_

30-1	3808-3817	Exclusion	_
30-2	3818-3826	criteria	_
30-3	3827-3831	were	_
30-4	3832-3833	:	_
30-5	3834-3841	cocaine	_
30-6	3842-3852	dependence	_
30-7	3853-3862	according	_
30-8	3863-3865	to	_
30-9	3866-3872	DSM-IV	_
30-10	3873-3881	criteria	_
30-11	3882-3883	;	_
30-12	3884-3887	use	_
30-13	3888-3890	of	_
30-14	3891-3903	psychotropic	_
30-15	3904-3913	medicinal	_
30-16	3914-3919	drugs	_
30-17	3920-3921	,	_
30-18	3922-3930	presence	_
30-19	3931-3933	or	_
30-20	3934-3941	history	_
30-21	3942-3944	of	_
30-22	3945-3956	psychiatric	_
30-23	3957-3959	or	_
30-24	3960-3972	neurological	_
30-25	3973-3981	disorder	_
30-26	3982-3983	;	_
30-27	3984-3993	pregnancy	_
30-28	3994-3996	or	_
30-29	3997-4006	lactating	_
30-30	4007-4008	;	_
30-31	4009-4023	cardiovascular	_
30-32	4024-4037	abnormalities	_
30-33	4038-4039	;	_
30-34	4040-4049	excessive	_
30-35	4050-4057	alcohol	_
30-36	4058-4061	use	_
30-37	4062-4063	(	_
30-38	4064-4065	>	_
30-39	4066-4068	20	_
30-40	4069-4079	units/week	_
30-41	4080-4081	)	_
30-42	4082-4084	or	_
30-43	4085-4092	smoking	_
30-44	4093-4094	(	_
30-45	4095-4096	>	_
30-46	4097-4099	15	_
30-47	4100-4114	cigarettes/day	_
30-48	4115-4116	)	_
30-49	4117-4118	,	_
30-50	4119-4122	and	_
30-51	4123-4135	hypertension	_
30-52	4136-4137	.	_

31-1	4138-4142	This	_
31-2	4143-4148	study	_
31-3	4149-4150	(	_
31-4	4151-4156	Dutch	_
31-5	4157-4162	Trial	_
31-6	4163-4171	Register	_
31-7	4172-4173	,	_
31-8	4174-4179	trial	_
31-9	4180-4186	number	_
31-10	4187-4194	NTR2127	_
31-11	4195-4196	)	_
31-12	4197-4200	was	_
31-13	4201-4210	conducted	_
31-14	4211-4220	according	_
31-15	4221-4223	to	_
31-16	4224-4227	the	_
31-17	4228-4232	code	_
31-18	4233-4235	of	_
31-19	4236-4242	ethics	_
31-20	4243-4245	on	_
31-21	4246-4251	human	_
31-22	4252-4267	experimentation	_
31-23	4268-4270	as	_
31-24	4271-4280	described	_
31-25	4281-4283	in	_
31-26	4284-4287	the	_
31-27	4288-4299	declaration	_
31-28	4300-4302	of	_
31-29	4303-4311	Helsinki	_
31-30	4312-4313	(	_
31-31	4314-4318	1964	_
31-32	4319-4320	)	_
31-33	4321-4322	,	_
31-34	4323-4330	amended	_
31-35	4331-4333	in	_
31-36	4334-4339	Seoul	_
31-37	4340-4341	(	_
31-38	4342-4346	2008	_
31-39	4347-4348	)	_
31-40	4349-4350	.	_

32-1	4351-4354	The	_
32-2	4355-4360	study	_
32-3	4361-4369	protocol	_
32-4	4370-4373	was	_
32-5	4374-4382	approved	_
32-6	4383-4385	by	_
32-7	4386-4389	the	_
32-8	4390-4397	Medical	_
32-9	4398-4404	Ethics	_
32-10	4405-4414	Committee	_
32-11	4415-4417	of	_
32-12	4418-4428	Maastricht	_
32-13	4429-4439	University	_
32-14	4440-4441	.	_

33-1	4442-4448	Design	_
33-2	4449-4450	,	_
33-3	4451-4455	drug	_
33-4	4456-4460	dose	_
33-5	4461-4464	and	_
33-6	4465-4479	administration	_
33-7	4480-4492	Participants	_
33-8	4493-4500	entered	_
33-9	4501-4502	a	_
33-10	4503-4515	double-blind	_
33-11	4516-4517	,	_
33-12	4518-4536	placebo-controlled	_
33-13	4537-4538	,	_
33-14	4539-4544	3-way	_
33-15	4545-4554	crossover	_
33-16	4555-4560	study	_
33-17	4561-4562	.	_

34-1	4563-4573	Treatments	_
34-2	4574-4583	consisted	_
34-3	4584-4586	of	_
34-4	4587-4594	placebo	_
34-5	4595-4596	,	_
34-6	4597-4600	450	_
34-7	4601-4606	μg/kg	_
34-8	4607-4610	THC	_
34-9	4611-4612	(	_
34-10	4613-4621	cannabis	_
34-11	4622-4627	plant	_
34-12	4628-4636	material	_
34-13	4637-4638	,	_
34-14	4639-4646	divided	_
34-15	4647-4651	over	_
34-16	4652-4653	2	_
34-17	4654-4664	successive	_
34-18	4665-4670	doses	_
34-19	4671-4673	of	_
34-20	4674-4677	300	_
34-21	4678-4681	and	_
34-22	4682-4685	150	_
34-23	4686-4691	μg/kg	_
34-24	4692-4693	)	_
34-25	4694-4697	and	_
34-26	4698-4699	a	_
34-27	4700-4706	single	_
34-28	4707-4711	dose	_
34-29	4712-4714	of	_
34-30	4715-4718	300	_
34-31	4719-4721	mg	_
34-32	4722-4729	cocaine	_
34-33	4730-4733	HCl	_
34-34	4734-4735	.	_

35-1	4736-4744	Cannabis	_
35-2	4745-4748	was	_
35-3	4749-4757	prepared	_
35-4	4758-4762	from	_
35-5	4763-4770	batches	_
35-6	4771-4775	that	_
35-7	4776-4785	contained	_
35-8	4786-4791	11–12	_
35-9	4792-4793	%	_
35-10	4794-4797	THC	_
35-11	4798-4799	.	_

36-1	4800-4808	Cannabis	_
36-2	4809-4814	doses	_
36-3	4815-4819	were	_
36-4	4820-4828	tailored	_
36-5	4829-4831	to	_
36-6	4832-4836	each	_
36-7	4837-4847	individual	_
36-8	4848-4855	subject	_
36-9	4856-4858	to	_
36-10	4859-4868	represent	_
36-11	4869-4875	weight	_
36-12	4876-4886	calibrated	_
36-13	4887-4892	doses	_
36-14	4893-4895	of	_
36-15	4896-4899	300	_
36-16	4900-4905	μg/kg	_
36-17	4906-4909	THC	_
36-18	4910-4913	and	_
36-19	4914-4917	150	_
36-20	4918-4923	μg/kg	_
36-21	4924-4927	THC	_
36-22	4928-4931	and	_
36-23	4932-4944	administered	_
36-24	4945-4950	using	_
36-25	4951-4952	a	_
36-26	4953-4960	Volcano	_
36-27	4961-4970	vaporizer	_
36-28	4971-4972	(	_
36-29	4973-4978	Storz	_
36-30	4979-4980	&	_
36-31	4981-4987	Bickel	_
36-32	4988-4995	Volcano	_
36-33	4996-4997	®	_
36-34	4998-4999	)	_
36-35	5000-5001	.	_

37-1	5002-5009	Cocaine	_
37-2	5010-5013	HCl	_
37-3	5014-5017	and	_
37-4	5018-5025	placebo	_
37-5	5026-5030	were	_
37-6	5031-5043	administered	_
37-7	5044-5046	in	_
37-8	5047-5049	an	_
37-9	5050-5056	opaque	_
37-10	5057-5062	white	_
37-11	5063-5070	capsule	_
37-12	5071-5072	.	_

38-1	5073-5083	Treatments	_
38-2	5084-5088	were	_
38-3	5089-5101	administered	_
38-4	5102-5107	using	_
38-5	5108-5109	a	_
38-6	5110-5116	double	_
38-7	5117-5122	dummy	_
38-8	5123-5132	technique	_
38-9	5133-5135	to	_
38-10	5136-5147	synchronize	_
38-11	5148-5152	time	_
38-12	5153-5155	of	_
38-13	5156-5163	maximal	_
38-14	5164-5168	drug	_
38-15	5169-5183	concentrations	_
38-16	5184-5185	(	_
38-17	5186-5190	Tmax	_
38-18	5191-5192	)	_
38-19	5193-5199	during	_
38-20	5200-5211	performance	_
38-21	5212-5219	testing	_
38-22	5220-5223	and	_
38-23	5224-5231	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-24	5232-5237	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-25	5238-5242	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-26	5243-5244	.	_

39-1	5245-5252	Cocaine	_
39-2	5253-5255	or	_
39-3	5256-5263	cocaine	_
39-4	5264-5271	placebo	_
39-5	5272-5280	capsules	_
39-6	5281-5285	were	_
39-7	5286-5298	administered	_
39-8	5299-5301	at	_
39-9	5302-5306	1,25	_
39-10	5307-5308	h	_
39-11	5309-5314	prior	_
39-12	5315-5316	(	_
39-13	5317-5319	T0	_
39-14	5320-5321	)	_
39-15	5322-5324	to	_
39-16	5325-5335	assessment	_
39-17	5336-5338	of	_
39-18	5339-5350	performance	_
39-19	5351-5353	in	_
39-20	5354-5357	the	_
39-21	5358-5362	MFFT	_
39-22	5363-5364	,	_
39-23	5365-5372	whereas	_
39-24	5373-5376	the	_
39-25	5377-5382	first	_
39-26	5383-5387	dose	_
39-27	5388-5390	of	_
39-28	5391-5399	cannabis	_
39-29	5400-5401	(	_
39-30	5402-5405	300	_
39-31	5406-5411	μg/kg	_
39-32	5412-5415	THC	_
39-33	5416-5417	)	_
39-34	5418-5420	or	_
39-35	5421-5429	cannabis	_
39-36	5430-5437	placebo	_
39-37	5438-5441	was	_
39-38	5442-5449	inhaled	_
39-39	5450-5452	15	_
39-40	5453-5454	(	_
39-41	5455-5457	T1	_
39-42	5458-5459	)	_
39-43	5460-5463	min	_
39-44	5464-5469	prior	_
39-45	5470-5472	to	_
39-46	5473-5477	MFFT	_
39-47	5478-5479	.	_

40-1	5480-5481	A	_
40-2	5482-5488	second	_
40-3	5489-5493	dose	_
40-4	5494-5495	(	_
40-5	5496-5498	T2	_
40-6	5499-5500	)	_
40-7	5501-5503	of	_
40-8	5504-5512	cannabis	_
40-9	5513-5514	(	_
40-10	5515-5518	150	_
40-11	5519-5524	μg/kg	_
40-12	5525-5528	THC	_
40-13	5529-5530	)	_
40-14	5531-5533	or	_
40-15	5534-5542	cannabis	_
40-16	5543-5550	placebo	_
40-17	5551-5554	was	_
40-18	5555-5567	administered	_
40-19	5568-5571	one	_
40-20	5572-5576	hour	_
40-21	5577-5582	after	_
40-22	5583-5586	the	_
40-23	5587-5592	first	_
40-24	5593-5597	dose	_
40-25	5598-5599	(	_
40-26	5600-5602	T1	_
40-27	5603-5604	)	_
40-28	5605-5608	and	_
40-29	5609-5611	30	_
40-30	5612-5615	min	_
40-31	5616-5621	prior	_
40-32	5622-5624	to	_
40-33	5625-5632	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
40-34	5633-5638	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
40-35	5639-5643	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
40-36	5644-5645	.	_

41-1	5646-5650	MFFT	_
41-2	5651-5662	performance	_
41-3	5663-5666	was	_
41-4	5667-5676	collected	_
41-5	5677-5681	from	_
41-6	5682-5694	participants	_
41-7	5695-5697	in	_
41-8	5698-5702	both	_
41-9	5703-5710	centers	_
41-10	5711-5712	.	_

42-1	5713-5720	However	_
42-2	5721-5725	only	_
42-3	5726-5738	participants	_
42-4	5739-5748	recruited	_
42-5	5749-5751	by	_
42-6	5752-5755	the	_
42-7	5756-5766	Maastricht	_
42-8	5767-5773	center	_
42-9	5774-5775	(	_
42-10	5776-5777	N	_
42-11	5778-5779	=	_
42-12	5780-5782	61	_
42-13	5783-5784	)	_
42-14	5785-5793	received	_
42-15	5794-5795	a	_
42-16	5796-5806	subsequent	_
42-17	5807-5811	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
42-18	5812-5819	session	_
42-19	5820-5821	.	_

43-1	5822-5831	Treatment	_
43-2	5832-5842	conditions	_
43-3	5843-5847	were	_
43-4	5848-5857	separated	_
43-5	5858-5860	by	_
43-6	5861-5862	a	_
43-7	5863-5870	minimum	_
43-8	5871-5879	wash-out	_
43-9	5880-5886	period	_
43-10	5887-5889	of	_
43-11	5890-5891	7	_
43-12	5892-5896	days	_
43-13	5897-5900	and	_
43-14	5901-5916	counterbalanced	_
43-15	5917-5923	across	_
43-16	5924-5936	participants	_
43-17	5937-5938	.	_

44-1	5939-5944	Vital	_
44-2	5945-5950	signs	_
44-3	5951-5954	and	_
44-4	5955-5960	blood	_
44-5	5961-5968	samples	_
44-6	5969-5973	were	_
44-7	5974-5979	taken	_
44-8	5980-5985	after	_
44-9	5986-5995	treatment	_
44-10	5996-6011	administrations	_
44-11	6012-6013	(	_
44-12	6014-6016	T0	_
44-13	6017-6018	,	_
44-14	6019-6021	T1	_
44-15	6022-6025	and	_
44-16	6026-6028	T2	_
44-17	6029-6030	)	_
44-18	6031-6032	.	_

45-1	6033-6043	Procedures	_
45-2	6044-6056	Participants	_
45-3	6057-6061	were	_
45-4	6062-6074	familiarized	_
45-5	6075-6079	with	_
45-6	6080-6085	tests	_
45-7	6086-6089	and	_
45-8	6090-6100	procedures	_
45-9	6101-6103	on	_
45-10	6104-6105	a	_
45-11	6106-6114	separate	_
45-12	6115-6123	training	_
45-13	6124-6127	day	_
45-14	6128-6133	prior	_
45-15	6134-6136	to	_
45-16	6137-6140	the	_
45-17	6141-6150	treatment	_
45-18	6151-6161	conditions	_
45-19	6162-6163	.	_

46-1	6164-6176	Participants	_
46-2	6177-6181	were	_
46-3	6182-6192	instructed	_
46-4	6193-6195	to	_
46-5	6196-6203	refrain	_
46-6	6204-6208	from	_
46-7	6209-6213	drug	_
46-8	6214-6217	use	_
46-9	6218-6219	(	_
46-10	6220-6226	except	_
46-11	6227-6230	for	_
46-12	6231-6239	cannabis	_
46-13	6240-6241	)	_
46-14	6242-6252	throughout	_
46-15	6253-6258	study	_
46-16	6259-6272	participation	_
46-17	6273-6274	.	_

47-1	6275-6277	In	_
47-2	6278-6281	the	_
47-3	6282-6289	morning	_
47-4	6290-6292	of	_
47-5	6293-6297	test	_
47-6	6298-6302	days	_
47-7	6303-6304	,	_
47-8	6305-6312	absence	_
47-9	6313-6315	of	_
47-10	6316-6331	benzodiazepines	_
47-11	6332-6333	,	_
47-12	6334-6341	opiates	_
47-13	6342-6343	,	_
47-14	6344-6351	cocaine	_
47-15	6352-6353	,	_
47-16	6354-6363	marijuana	_
47-17	6364-6365	,	_
47-18	6366-6370	MDMA	_
47-19	6371-6374	and	_
47-20	6375-6376	(	_
47-21	6377-6381	meth	_
47-22	6382-6383	)	_
47-23	6384-6395	amphetamine	_
47-24	6396-6399	was	_
47-25	6400-6408	assessed	_
47-26	6409-6414	using	_
47-27	6415-6420	urine	_
47-28	6421-6428	screens	_
47-29	6429-6432	and	_
47-30	6433-6436	the	_
47-31	6437-6444	absence	_
47-32	6445-6447	of	_
47-33	6448-6455	alcohol	_
47-34	6456-6459	was	_
47-35	6460-6468	measured	_
47-36	6469-6474	using	_
47-37	6475-6476	a	_
47-38	6477-6489	breathalyzer	_
47-39	6490-6491	.	_

48-1	6492-6498	Female	_
48-2	6499-6511	participants	_
48-3	6512-6521	underwent	_
48-4	6522-6524	an	_
48-5	6525-6535	additional	_
48-6	6536-6545	pregnancy	_
48-7	6546-6550	test	_
48-8	6551-6552	.	_

49-1	6553-6565	Participants	_
49-2	6566-6570	were	_
49-3	6571-6575	only	_
49-4	6576-6583	allowed	_
49-5	6584-6586	to	_
49-6	6587-6594	proceed	_
49-7	6595-6599	when	_
49-8	6600-6604	test	_
49-9	6605-6612	results	_
49-10	6613-6616	for	_
49-11	6617-6621	drug	_
49-12	6622-6623	(	_
49-13	6624-6630	except	_
49-14	6631-6639	cannabis	_
49-15	6640-6641	)	_
49-16	6642-6645	and	_
49-17	6646-6653	alcohol	_
49-18	6654-6657	use	_
49-19	6658-6661	and	_
49-20	6662-6671	pregnancy	_
49-21	6672-6676	were	_
49-22	6677-6685	negative	_
49-23	6686-6687	.	_

50-1	6688-6700	Participants	_
50-2	6701-6705	that	_
50-3	6706-6712	passed	_
50-4	6713-6716	the	_
50-5	6717-6723	screen	_
50-6	6724-6728	test	_
50-7	6729-6737	received	_
50-8	6738-6739	a	_
50-9	6740-6748	standard	_
50-10	6749-6758	breakfast	_
50-11	6759-6760	,	_
50-12	6761-6769	followed	_
50-13	6770-6772	by	_
50-14	6773-6781	baseline	_
50-15	6782-6790	measures	_
50-16	6791-6793	of	_
50-17	6794-6799	vital	_
50-18	6800-6805	signs	_
50-19	6806-6807	(	_
50-20	6808-6813	blood	_
50-21	6814-6822	pressure	_
50-22	6823-6826	and	_
50-23	6827-6832	heart	_
50-24	6833-6837	rate	_
50-25	6838-6839	)	_
50-26	6840-6843	and	_
50-27	6844-6845	a	_
50-28	6846-6852	sample	_
50-29	6853-6855	of	_
50-30	6856-6861	blood	_
50-31	6862-6863	.	_

51-1	6864-6872	Matching	_
51-2	6873-6881	familiar	_
51-3	6882-6889	figures	_
51-4	6890-6894	test	_
51-5	6895-6896	(	_
51-6	6897-6901	MFFT	_
51-7	6902-6903	)	_
51-8	6904-6907	The	_
51-9	6908-6912	MFFT	_
51-10	6913-6921	measures	_
51-11	6922-6931	cognitive	_
51-12	6932-6943	impulsivity	_
51-13	6944-6945	.	_

52-1	6946-6948	It	_
52-2	6949-6957	involves	_
52-3	6958-6970	simultaneous	_
52-4	6971-6983	presentation	_
52-5	6984-6986	of	_
52-6	6987-6988	a	_
52-7	6989-6995	target	_
52-8	6996-7002	figure	_
52-9	7003-7011	centered	_
52-10	7012-7014	on	_
52-11	7015-7018	the	_
52-12	7019-7023	left	_
52-13	7024-7028	half	_
52-14	7029-7031	of	_
52-15	7032-7035	the	_
52-16	7036-7042	screen	_
52-17	7043-7046	and	_
52-18	7047-7049	an	_
52-19	7050-7055	array	_
52-20	7056-7058	of	_
52-21	7059-7062	six	_
52-22	7063-7075	alternatives	_
52-23	7076-7078	on	_
52-24	7079-7082	the	_
52-25	7083-7088	right	_
52-26	7089-7093	half	_
52-27	7094-7096	of	_
52-28	7097-7100	the	_
52-29	7101-7107	screen	_
52-30	7108-7109	,	_
52-31	7110-7113	all	_
52-32	7114-7120	except	_
52-33	7121-7124	one	_
52-34	7125-7134	differing	_
52-35	7135-7137	in	_
52-36	7138-7141	one	_
52-37	7142-7144	or	_
52-38	7145-7149	more	_
52-39	7150-7157	details	_
52-40	7158-7162	from	_
52-41	7163-7166	the	_
52-42	7167-7173	target	_
52-43	7174-7180	figure	_
52-44	7181-7182	.	_

53-1	7183-7186	The	_
53-2	7187-7199	participants	_
53-3	7200-7203	are	_
53-4	7204-7209	asked	_
53-5	7210-7212	to	_
53-6	7213-7217	find	_
53-7	7218-7221	the	_
53-8	7222-7226	item	_
53-9	7227-7231	that	_
53-10	7232-7239	exactly	_
53-11	7240-7247	matches	_
53-12	7248-7251	the	_
53-13	7252-7258	target	_
53-14	7259-7263	item	_
53-15	7264-7266	by	_
53-16	7267-7275	pressing	_
53-17	7276-7277	a	_
53-18	7278-7286	keyboard	_
53-19	7287-7293	number	_
53-20	7294-7307	corresponding	_
53-21	7308-7310	to	_
53-22	7311-7315	each	_
53-23	7316-7318	of	_
53-24	7319-7322	the	_
53-25	7323-7328	items	_
53-26	7329-7330	.	_

54-1	7331-7333	If	_
54-2	7334-7337	the	_
54-3	7338-7345	initial	_
54-4	7346-7355	selection	_
54-5	7356-7358	is	_
54-6	7359-7368	incorrect	_
54-7	7369-7370	,	_
54-8	7371-7375	this	_
54-9	7376-7378	is	_
54-10	7379-7387	signaled	_
54-11	7388-7392	with	_
54-12	7393-7394	a	_
54-13	7395-7399	beep	_
54-14	7400-7403	and	_
54-15	7404-7416	participants	_
54-16	7417-7420	are	_
54-17	7421-7430	requested	_
54-18	7431-7433	to	_
54-19	7434-7441	respond	_
54-20	7442-7447	again	_
54-21	7448-7449	.	_

55-1	7450-7454	Each	_
55-2	7455-7462	subject	_
55-3	7463-7465	is	_
55-4	7466-7471	given	_
55-5	7472-7473	2	_
55-6	7474-7482	practice	_
55-7	7483-7489	trials	_
55-8	7490-7498	followed	_
55-9	7499-7501	by	_
55-10	7502-7504	20	_
55-11	7505-7509	test	_
55-12	7510-7516	trials	_
55-13	7517-7518	.	_

56-1	7519-7523	Mean	_
56-2	7524-7531	latency	_
56-3	7532-7534	of	_
56-4	7535-7538	the	_
56-5	7539-7544	first	_
56-6	7545-7553	response	_
56-7	7554-7557	and	_
56-8	7558-7563	total	_
56-9	7564-7570	number	_
56-10	7571-7573	of	_
56-11	7574-7580	errors	_
56-12	7581-7582	,	_
56-13	7583-7586	are	_
56-14	7587-7595	recorded	_
56-15	7596-7599	and	_
56-16	7600-7604	used	_
56-17	7605-7607	to	_
56-18	7608-7617	calculate	_
56-19	7618-7621	two	_
56-20	7622-7629	primary	_
56-21	7630-7638	measures	_
56-22	7639-7644	after	_
56-23	7645-7661	z-transformation	_
56-24	7662-7663	:	_
56-25	7664-7667	i.e	_
56-26	7668-7669	.	_

57-1	7670-7672	an	_
57-2	7673-7684	Impulsivity	_
57-3	7685-7690	score	_
57-4	7691-7692	(	_
57-5	7693-7700	I-score	_
57-6	7701-7702	)	_
57-7	7703-7706	and	_
57-8	7707-7709	an	_
57-9	7710-7720	Efficiency	_
57-10	7721-7726	score	_
57-11	7727-7728	(	_
57-12	7729-7736	E-score	_
57-13	7737-7738	)	_
57-14	7739-7740	(	_
57-15	7741-7747	Messer	_
57-16	7748-7751	and	_
57-17	7752-7762	Brodzinsky	_
57-18	7763-7764	)	_
57-19	7765-7766	.	_

58-1	7767-7770	The	_
58-2	7771-7778	I-score	_
58-3	7779-7781	is	_
58-4	7782-7783	a	_
58-5	7784-7793	composite	_
58-6	7794-7799	index	_
58-7	7800-7802	of	_
58-8	7803-7814	impulsivity	_
58-9	7815-7818	and	_
58-10	7819-7821	is	_
58-11	7822-7832	calculated	_
58-12	7833-7835	by	_
58-13	7836-7847	subtracting	_
58-14	7848-7851	the	_
58-15	7852-7864	standardized	_
58-16	7865-7870	score	_
58-17	7871-7873	of	_
58-18	7874-7877	the	_
58-19	7878-7882	mean	_
58-20	7883-7890	latency	_
58-21	7891-7893	to	_
58-22	7894-7899	first	_
58-23	7900-7908	response	_
58-24	7909-7913	from	_
58-25	7914-7917	the	_
58-26	7918-7930	standardized	_
58-27	7931-7936	score	_
58-28	7937-7939	of	_
58-29	7940-7943	the	_
58-30	7944-7949	total	_
58-31	7950-7956	number	_
58-32	7957-7959	of	_
58-33	7960-7966	errors	_
58-34	7967-7976	committed	_
58-35	7977-7978	(	_
58-36	7979-7994	Zerror-Zlatency	_
58-37	7995-7996	)	_
58-38	7997-7998	.	_

59-1	7999-8002	The	_
59-2	8003-8010	E-score	_
59-3	8011-8013	is	_
59-4	8014-8024	calculated	_
59-5	8025-8027	by	_
59-6	8028-8035	summing	_
59-7	8036-8039	the	_
59-8	8040-8052	standardized	_
59-9	8053-8058	score	_
59-10	8059-8061	of	_
59-11	8062-8065	the	_
59-12	8066-8070	mean	_
59-13	8071-8078	latency	_
59-14	8079-8081	to	_
59-15	8082-8087	first	_
59-16	8088-8096	response	_
59-17	8097-8101	from	_
59-18	8102-8105	the	_
59-19	8106-8118	standardized	_
59-20	8119-8124	score	_
59-21	8125-8127	of	_
59-22	8128-8131	the	_
59-23	8132-8137	total	_
59-24	8138-8144	number	_
59-25	8145-8147	of	_
59-26	8148-8154	errors	_
59-27	8155-8164	committed	_
59-28	8165-8166	(	_
59-29	8167-8169	1-	_
59-30	8170-8171	(	_
59-31	8172-8178	Zerror	_
59-32	8179-8180	+	_
59-33	8181-8189	Zlatency	_
59-34	8190-8191	)	_
59-35	8192-8193	)	_
59-36	8194-8195	.	_

60-1	8196-8203	Resting	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-2	8204-8209	state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-3	8210-8214	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-4	8215-8218	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-5	8219-8225	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
60-6	8226-8230	were	_
60-7	8231-8239	obtained	_
60-8	8240-8242	in	_
60-9	8243-8244	a	_
60-10	8245-8246	3	_
60-11	8247-8248	T	_
60-12	8249-8258	head-only	_
60-13	8259-8266	scanner	_
60-14	8267-8268	(	_
60-15	8269-8277	Siemens®	_
60-16	8278-8286	MAGNETOM	_
60-17	8287-8294	Allegra	_
60-18	8295-8296	)	_
60-19	8297-8298	.	_

61-1	8299-8305	During	_
61-2	8306-8313	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
61-3	8314-8319	state	_
61-4	8320-8323	240	_
61-5	8324-8327	EPI	_
61-6	8328-8333	whole	_
61-7	8334-8339	brain	_
61-8	8340-8350	functional	_
61-9	8351-8358	volumes	_
61-10	8359-8363	were	_
61-11	8364-8372	acquired	_
61-12	8373-8374	(	_
61-13	8375-8377	TR	_
61-14	8378-8379	=	_
61-15	8380-8381	2	_
61-16	8382-8383	s	_
61-17	8384-8385	,	_
61-18	8386-8388	TE	_
61-19	8389-8390	=	_
61-20	8391-8393	30	_
61-21	8394-8396	ms	_
61-22	8397-8398	,	_
61-23	8399-8403	flip	_
61-24	8404-8409	angle	_
61-25	8410-8411	=	_
61-26	8412-8415	90°	_
61-27	8416-8417	,	_
61-28	8418-8424	matrix	_
61-29	8425-8426	=	_
61-30	8427-8429	64	_
61-31	8430-8431	×	_
61-32	8432-8434	64	_
61-33	8435-8436	×	_
61-34	8437-8439	32	_
61-35	8440-8441	,	_
61-36	8442-8447	voxel	_
61-37	8448-8452	size	_
61-38	8453-8454	=	_
61-39	8455-8458	3.5	_
61-40	8459-8460	×	_
61-41	8461-8464	3.5	_
61-42	8465-8466	×	_
61-43	8467-8470	3.5	_
61-44	8471-8473	mm	_
61-45	8474-8475	)	_
61-46	8476-8477	.	_

62-1	8478-8488	Volunteers	_
62-2	8489-8493	were	_
62-3	8494-8499	asked	_
62-4	8500-8502	to	_
62-5	8503-8508	relax	_
62-6	8509-8513	with	_
62-7	8514-8517	the	_
62-8	8518-8522	eyes	_
62-9	8523-8527	open	_
62-10	8528-8534	during	_
62-11	8535-8542	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
62-12	8543-8548	state	_
62-13	8549-8560	measurement	_
62-14	8561-8562	.	_

63-1	8563-8566	For	_
63-2	8567-8577	anatomical	_
63-3	8578-8587	reference	_
63-4	8588-8589	,	_
63-5	8590-8591	a	_
63-6	8592-8594	3D	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
63-7	8595-8601	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
63-8	8602-8603	(	_
63-9	8604-8626	magnetization-prepared	_
63-10	8627-8632	rapid	_
63-11	8633-8641	gradient	_
63-12	8642-8646	echo	_
63-13	8647-8648	;	_
63-14	8649-8651	TR	_
63-15	8652-8653	=	_
63-16	8654-8657	9.7	_
63-17	8658-8660	ms	_
63-18	8661-8662	,	_
63-19	8663-8665	TE	_
63-20	8666-8667	=	_
63-21	8668-8669	4	_
63-22	8670-8672	ms	_
63-23	8673-8674	,	_
63-24	8675-8679	flip	_
63-25	8680-8685	angle	_
63-26	8686-8687	=	_
63-27	8688-8691	12°	_
63-28	8692-8693	,	_
63-29	8694-8700	matrix	_
63-30	8701-8702	=	_
63-31	8703-8706	256	_
63-32	8707-8708	×	_
63-33	8709-8712	256	_
63-34	8713-8714	,	_
63-35	8715-8720	voxel	_
63-36	8721-8725	size	_
63-37	8726-8727	=	_
63-38	8728-8729	1	_
63-39	8730-8731	×	_
63-40	8732-8733	1	_
63-41	8734-8735	×	_
63-42	8736-8737	1	_
63-43	8738-8741	mm3	_
63-44	8742-8743	)	_
63-45	8744-8749	image	_
63-46	8750-8754	data	_
63-47	8755-8758	set	_
63-48	8759-8762	was	_
63-49	8763-8771	acquired	_
63-50	8772-8773	.	_

64-1	8774-8777	The	_
64-2	8778-8782	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
64-3	8783-8787	data	_
64-4	8788-8792	were	_
64-5	8793-8805	preprocessed	_
64-6	8806-8811	using	_
64-7	8812-8816	SPM8	_
64-8	8817-8825	software	_
64-9	8826-8827	(	_
64-10	8828-8835	Welcome	_
64-11	8836-8841	Trust	_
64-12	8842-8848	Center	_
64-13	8849-8852	for	_
64-14	8853-8865	Neuroimaging	_
64-15	8866-8867	,	_
64-16	8868-8874	London	_
64-17	8875-8876	,	_
64-18	8877-8879	UK	_
64-19	8880-8881	)	_
64-20	8882-8883	.	_

65-1	8884-8887	The	_
65-2	8888-8893	first	_
65-3	8894-8895	2	_
65-4	8896-8903	volumes	_
65-5	8904-8908	were	_
65-6	8909-8916	removed	_
65-7	8917-8921	from	_
65-8	8922-8926	each	_
65-9	8927-8931	fMRI	_
65-10	8932-8936	data	_
65-11	8937-8940	set	_
65-12	8941-8943	to	_
65-13	8944-8949	allow	_
65-14	8950-8953	for	_
65-15	8954-8962	magnetic	_
65-16	8963-8976	equilibration	_
65-17	8977-8978	.	_

66-1	8979-8992	Preprocessing	_
66-2	8993-9001	included	_
66-3	9002-9004	3D	_
66-4	9005-9011	motion	_
66-5	9012-9022	correction	_
66-6	9023-9026	and	_
66-7	9027-9032	slice	_
66-8	9033-9037	time	_
66-9	9038-9048	correction	_
66-10	9049-9050	.	_

67-1	9051-9061	Individual	_
67-2	9062-9072	anatomical	_
67-3	9073-9077	data	_
67-4	9078-9082	sets	_
67-5	9083-9087	were	_
67-6	9088-9098	normalized	_
67-7	9099-9101	to	_
67-8	9102-9110	standard	_
67-9	9111-9114	3-D	_
67-10	9115-9118	MNI	_
67-11	9119-9124	space	_
67-12	9125-9126	.	_

68-1	9127-9137	Individual	_
68-2	9138-9148	functional	_
68-3	9149-9155	images	_
68-4	9156-9160	were	_
68-5	9161-9170	realigned	_
68-6	9171-9172	,	_
68-7	9173-9186	co-registered	_
68-8	9187-9190	and	_
68-9	9191-9201	normalized	_
68-10	9202-9204	to	_
68-11	9205-9208	the	_
68-12	9209-9219	anatomical	_
68-13	9220-9224	data	_
68-14	9225-9226	,	_
68-15	9227-9230	and	_
68-16	9231-9240	resampled	_
68-17	9241-9243	to	_
68-18	9244-9245	a	_
68-19	9246-9251	voxel	_
68-20	9252-9256	size	_
68-21	9257-9259	of	_
68-22	9260-9261	3	_
68-23	9262-9263	×	_
68-24	9264-9265	3	_
68-25	9266-9267	×	_
68-26	9268-9269	3	_
68-27	9270-9273	mm3	_
68-28	9274-9275	.	_

69-1	9276-9283	Spatial	_
69-2	9284-9293	smoothing	_
69-3	9294-9297	was	_
69-4	9298-9307	conducted	_
69-5	9308-9312	with	_
69-6	9313-9314	a	_
69-7	9315-9319	FWHM	_
69-8	9320-9321	4	_
69-9	9322-9324	mm	_
69-10	9325-9333	Gaussian	_
69-11	9334-9340	kernel	_
69-12	9341-9342	.	_

70-1	9343-9353	Functional	_
70-2	9354-9366	connectivity	_
70-3	9367-9377	Functional	_
70-4	9378-9390	connectivity	_
70-5	9391-9395	data	_
70-6	9396-9400	were	_
70-7	9401-9409	produced	_
70-8	9410-9414	with	_
70-9	9415-9418	the	_
70-10	9419-9425	MATLAB	_
70-11	9426-9433	toolbox	_
70-12	9434-9441	DPARSFA	_
70-13	9442-9443	(	_
70-14	9444-9452	Chao-Gan	_
70-15	9453-9456	and	_
70-16	9457-9464	Yu-Feng	_
70-17	9465-9466	)	_
70-18	9467-9468	.	_

71-1	9469-9474	First	_
71-2	9475-9476	,	_
71-3	9477-9483	linear	_
71-4	9484-9490	trends	_
71-5	9491-9493	of	_
71-6	9494-9498	time	_
71-7	9499-9506	courses	_
71-8	9507-9511	were	_
71-9	9512-9519	removed	_
71-10	9520-9528	followed	_
71-11	9529-9531	by	_
71-12	9532-9535	low	_
71-13	9536-9545	band-pass	_
71-14	9546-9555	filtering	_
71-15	9556-9557	(	_
71-16	9558-9567	0.01–0.08	_
71-17	9568-9570	Hz	_
71-18	9571-9572	)	_
71-19	9573-9575	of	_
71-20	9576-9579	the	_
71-21	9580-9592	preprocessed	_
71-22	9593-9597	data	_
71-23	9598-9600	to	_
71-24	9601-9607	remove	_
71-25	9608-9609	‘	_
71-26	9610-9615	noise	_
71-27	9616-9617	’	_
71-28	9618-9630	attributable	_
71-29	9631-9633	to	_
71-30	9634-9647	physiological	_
71-31	9648-9658	parameters	_
71-32	9659-9660	.	_

72-1	9661-9663	In	_
72-2	9664-9672	addition	_
72-3	9673-9674	,	_
72-4	9675-9683	nuisance	_
72-5	9684-9694	covariates	_
72-6	9695-9704	including	_
72-7	9705-9706	6	_
72-8	9707-9713	motion	_
72-9	9714-9724	parameters	_
72-10	9725-9726	,	_
72-11	9727-9730	the	_
72-12	9731-9736	white	_
72-13	9737-9743	matter	_
72-14	9744-9750	signal	_
72-15	9751-9754	and	_
72-16	9755-9758	the	_
72-17	9759-9762	CSF	_
72-18	9763-9769	signal	_
72-19	9770-9774	were	_
72-20	9775-9782	removed	_
72-21	9783-9784	.	_

73-1	9785-9788	Two	_
73-2	9789-9796	spheres	_
73-3	9797-9798	(	_
73-4	9799-9805	radius	_
73-5	9806-9807	4	_
73-6	9808-9810	mm	_
73-7	9811-9812	)	_
73-8	9813-9817	were	_
73-9	9818-9825	created	_
73-10	9826-9830	that	_
73-11	9831-9835	were	_
73-12	9836-9843	located	_
73-13	9844-9845	(	_
73-14	9846-9848	in	_
73-15	9849-9852	MNI	_
73-16	9853-9858	space	_
73-17	9859-9860	)	_
73-18	9861-9863	in	_
73-19	9864-9867	the	_
73-20	9868-9871	NAc	_
73-21	9872-9874	of	_
73-22	9875-9878	the	_
73-23	9879-9883	left	_
73-24	9884-9885	(	_
73-25	9886-9888	−9	_
73-26	9889-9890	,	_
73-27	9891-9892	9	_
73-28	9893-9894	,	_
73-29	9895-9897	-9	_
73-30	9898-9899	)	_
73-31	9900-9903	and	_
73-32	9904-9909	right	_
73-33	9910-9911	(	_
73-34	9912-9913	9	_
73-35	9914-9915	,	_
73-36	9916-9917	9	_
73-37	9918-9919	,	_
73-38	9920-9922	-9	_
73-39	9923-9924	)	_
73-40	9925-9935	hemisphere	_
73-41	9936-9937	(	_
73-42	9938-9940	Di	_
73-43	9941-9948	Martino	_
73-44	9949-9951	et	_
73-45	9952-9954	al	_
73-46	9955-9956	.	_
73-47	9957-9958	)	_
73-48	9959-9960	.	_

74-1	9961-9968	Average	_
74-2	9969-9973	time	_
74-3	9974-9981	courses	_
74-4	9982-9986	were	_
74-5	9987-9995	obtained	_
74-6	9996-9999	for	_
74-7	10000-10004	each	_
74-8	10005-10011	sphere	_
74-9	10012-10022	separately	_
74-10	10023-10026	and	_
74-11	10027-10040	correlational	_
74-12	10041-10049	analysis	_
74-13	10050-10053	was	_
74-14	10054-10063	performed	_
74-15	10064-10069	voxel	_
74-16	10070-10074	wise	_
74-17	10075-10077	to	_
74-18	10078-10086	generate	_
74-19	10087-10097	functional	_
74-20	10098-10110	connectivity	_
74-21	10111-10115	maps	_
74-22	10116-10119	for	_
74-23	10120-10124	each	_
74-24	10125-10131	sphere	_
74-25	10132-10133	.	_

75-1	10134-10141	Finally	_
75-2	10142-10143	,	_
75-3	10144-10147	the	_
75-4	10148-10159	correlation	_
75-5	10160-10171	coefficient	_
75-6	10172-10175	map	_
75-7	10176-10179	was	_
75-8	10180-10189	converted	_
75-9	10190-10194	into	_
75-10	10195-10201	z-maps	_
75-11	10202-10204	by	_
75-12	10205-10211	Fisher	_
75-13	10212-10213	’	_
75-14	10214-10215	s	_
75-15	10216-10222	r-to-z	_
75-16	10223-10232	transform	_
75-17	10233-10235	to	_
75-18	10236-10243	improve	_
75-19	10244-10253	normality	_
75-20	10254-10255	.	_

76-1	10256-10268	Drug-induced	_
76-2	10269-10276	changes	_
76-3	10277-10279	in	_
76-4	10280-10290	functional	_
76-5	10291-10303	connectivity	_
76-6	10304-10306	of	_
76-7	10307-10310	the	_
76-8	10311-10314	NAc	_
76-9	10315-10319	have	_
76-10	10320-10324	been	_
76-11	10325-10330	shown	_
76-12	10331-10333	to	_
76-13	10334-10339	serve	_
76-14	10340-10342	as	_
76-15	10343-10344	a	_
76-16	10345-10351	useful	_
76-17	10352-10358	marker	_
76-18	10359-10361	of	_
76-19	10362-10366	drug	_
76-20	10367-10375	activity	_
76-21	10376-10378	in	_
76-22	10379-10381	in	_
76-23	10382-10385	the	_
76-24	10386-10391	brain	_
76-25	10392-10398	reward	_
76-26	10399-10406	circuit	_
76-27	10407-10408	(	_
76-28	10409-10418	Ramaekers	_
76-29	10419-10421	et	_
76-30	10422-10424	al	_
76-31	10425-10426	.	_
76-32	10427-10428	)	_
76-33	10429-10430	.	_

77-1	10431-10447	Pharmacokinetics	_
77-2	10448-10451	and	_
77-3	10452-10468	pharmacogenetics	_
77-4	10469-10474	Serum	_
77-5	10475-10478	was	_
77-6	10479-10483	used	_
77-7	10484-10487	for	_
77-8	10488-10497	detection	_
77-9	10498-10500	of	_
77-10	10501-10513	cannabinoids	_
77-11	10514-10521	whereas	_
77-12	10522-10529	cocaine	_
77-13	10530-10533	and	_
77-14	10534-10545	metabolites	_
77-15	10546-10550	were	_
77-16	10551-10561	determined	_
77-17	10562-10564	in	_
77-18	10565-10571	plasma	_
77-19	10572-10573	.	_

78-1	10574-10577	The	_
78-2	10578-10591	determination	_
78-3	10592-10594	of	_
78-4	10595-10618	Δ9-tetrahydrocannabinol	_
78-5	10619-10620	(	_
78-6	10621-10624	THC	_
78-7	10625-10626	)	_
78-8	10627-10628	,	_
78-9	10629-10643	11-hydroxy-THC	_
78-10	10644-10645	(	_
78-11	10646-10652	THC-OH	_
78-12	10653-10654	)	_
78-13	10655-10656	,	_
78-14	10657-10677	11-nor-9-carboxy-THC	_
78-15	10678-10679	(	_
78-16	10680-10688	THC-COOH	_
78-17	10689-10690	)	_
78-18	10691-10692	,	_
78-19	10693-10700	cocaine	_
78-20	10701-10702	(	_
78-21	10703-10706	COC	_
78-22	10707-10708	)	_
78-23	10709-10710	,	_
78-24	10711-10726	benzoylecgonine	_
78-25	10727-10728	(	_
78-26	10729-10732	BZE	_
78-27	10733-10734	)	_
78-28	10735-10738	and	_
78-29	10739-10747	ecgonine	_
78-30	10748-10754	methyl	_
78-31	10755-10760	ester	_
78-32	10761-10762	(	_
78-33	10763-10766	EME	_
78-34	10767-10768	)	_
78-35	10769-10771	in	_
78-36	10772-10778	plasma	_
78-37	10779-10782	was	_
78-38	10783-10792	performed	_
78-39	10793-10795	in	_
78-40	10796-10797	a	_
78-41	10798-10809	specialized	_
78-42	10810-10832	forensic-toxicological	_
78-43	10833-10843	laboratory	_
78-44	10844-10849	using	_
78-45	10850-10859	validated	_
78-46	10860-10870	procedures	_
78-47	10871-10876	38,39	_
78-48	10877-10878	.	_

79-1	10879-10882	DBH	_
79-2	10883-10891	genotype	_
79-3	10892-10895	was	_
79-4	10896-10904	analyzed	_
79-5	10905-10910	after	_
79-6	10911-10914	DNA	_
79-7	10915-10924	isolation	_
79-8	10925-10929	from	_
79-9	10930-10935	blood	_
79-10	10936-10945	collected	_
79-11	10946-10948	at	_
79-12	10949-10956	medical	_
79-13	10957-10966	screening	_
79-14	10967-10972	using	_
79-15	10973-10981	standard	_
79-16	10982-10991	protocols	_
79-17	10992-10993	.	_

80-1	10994-10997	The	_
80-2	10998-11001	DBH	_
80-3	11002-11014	polymorphism	_
80-4	11015-11016	(	_
80-5	11017-11026	rs1611115	_
80-6	11027-11028	)	_
80-7	11029-11032	was	_
80-8	11033-11042	genotyped	_
80-9	11043-11048	using	_
80-10	11049-11060	restriction	_
80-11	11061-11069	fragment	_
80-12	11070-11076	length	_
80-13	11077-11089	polymorphism	_
80-14	11090-11091	(	_
80-15	11092-11096	RFLP	_
80-16	11097-11098	)	_
80-17	11099-11107	analysis	_
80-18	11108-11109	.	_

81-1	11110-11113	PCR	_
81-2	11114-11117	was	_
81-3	11118-11127	performed	_
81-4	11128-11130	on	_
81-5	11131-11133	50	_
81-6	11134-11136	ng	_
81-7	11137-11144	genomic	_
81-8	11145-11148	DNA	_
81-9	11149-11154	using	_
81-10	11155-11158	0.2	_
81-11	11159-11161	μM	_
81-12	11162-11169	forward	_
81-13	11170-11176	primer	_
81-14	11177-11178	(	_
81-15	11179-11180	5	_
81-16	11181-11182	’	_
81-17	11183-11206	-TGAATGTGCCCCTAAGGCTA-3	_
81-18	11207-11208	’	_
81-19	11209-11210	)	_
81-20	11211-11214	and	_
81-21	11215-11218	0.2	_
81-22	11219-11221	μM	_
81-23	11222-11229	reverse	_
81-24	11230-11236	primer	_
81-25	11237-11238	(	_
81-26	11239-11240	5	_
81-27	11241-11242	’	_
81-28	11243-11270	-CACCTCTCCCTCCTGTCCTCTCGC-3	_
81-29	11271-11272	’	_
81-30	11273-11274	)	_
81-31	11275-11276	,	_
81-32	11277-11281	0.25	_
81-33	11282-11284	mM	_
81-34	11285-11290	dNTPs	_
81-35	11291-11292	,	_
81-36	11293-11294	2	_
81-37	11295-11296	U	_
81-38	11297-11300	Taq	_
81-39	11301-11304	DNA	_
81-40	11305-11315	polymerase	_
81-41	11316-11317	(	_
81-42	11318-11328	Invitrogen	_
81-43	11329-11330	,	_
81-44	11331-11336	Breda	_
81-45	11337-11338	,	_
81-46	11339-11342	The	_
81-47	11343-11354	Netherlands	_
81-48	11355-11356	)	_
81-49	11357-11359	in	_
81-50	11360-11361	a	_
81-51	11362-11364	1×	_
81-52	11365-11368	PCR	_
81-53	11369-11381	optimization	_
81-54	11382-11388	buffer	_
81-55	11389-11390	A	_
81-56	11391-11392	(	_
81-57	11393-11395	30	_
81-58	11396-11398	mM	_
81-59	11399-11407	Tris-HCl	_
81-60	11408-11410	pH	_
81-61	11411-11414	8.5	_
81-62	11415-11416	,	_
81-63	11417-11420	7.5	_
81-64	11421-11423	mM	_
81-65	11424-11425	(	_
81-66	11426-11429	NH4	_
81-67	11430-11431	)	_
81-68	11432-11436	2SO4	_
81-69	11437-11438	,	_
81-70	11439-11443	0.75	_
81-71	11444-11446	mM	_
81-72	11447-11452	MgCl2	_
81-73	11453-11454	)	_
81-74	11455-11456	.	_

82-1	11457-11460	The	_
82-2	11461-11468	cycling	_
82-3	11469-11479	conditions	_
82-4	11480-11484	were	_
82-5	11485-11486	5	_
82-6	11487-11490	min	_
82-7	11491-11493	92	_
82-8	11494-11496	°C	_
82-9	11497-11498	,	_
82-10	11499-11507	followed	_
82-11	11508-11510	by	_
82-12	11511-11513	35	_
82-13	11514-11520	cycles	_
82-14	11521-11523	of	_
82-15	11524-11525	1	_
82-16	11526-11529	min	_
82-17	11530-11532	92	_
82-18	11533-11535	°C	_
82-19	11536-11537	,	_
82-20	11538-11539	1	_
82-21	11540-11543	min	_
82-22	11544-11546	59	_
82-23	11547-11549	°C	_
82-24	11550-11551	,	_
82-25	11552-11553	1	_
82-26	11554-11557	min	_
82-27	11558-11560	72	_
82-28	11561-11564	°C.	_
82-29	11565-11566	,	_
82-30	11567-11570	and	_
82-31	11571-11572	a	_
82-32	11573-11583	subsequent	_
82-33	11584-11585	5	_
82-34	11586-11589	min	_
82-35	11590-11592	72	_
82-36	11593-11598	°C.To	_
82-37	11599-11605	purify	_
82-38	11606-11609	the	_
82-39	11610-11622	PCR-products	_
82-40	11623-11624	,	_
82-41	11625-11637	NucleoFast96	_
82-42	11638-11644	plates	_
82-43	11645-11646	(	_
82-44	11647-11661	Macherey-Nagel	_
82-45	11662-11663	,	_
82-46	11664-11669	Düren	_
82-47	11670-11671	,	_
82-48	11672-11679	Germany	_
82-49	11680-11681	)	_
82-50	11682-11686	were	_
82-51	11687-11691	used	_
82-52	11692-11693	.	_

83-1	11694-11705	Restriction	_
83-2	11706-11714	reaction	_
83-3	11715-11718	was	_
83-4	11719-11728	performed	_
83-5	11729-11731	in	_
83-6	11732-11733	a	_
83-7	11734-11739	total	_
83-8	11740-11746	volume	_
83-9	11747-11749	of	_
83-10	11750-11752	15	_
83-11	11753-11755	μl	_
83-12	11756-11757	,	_
83-13	11758-11768	containing	_
83-14	11769-11771	10	_
83-15	11772-11774	μl	_
83-16	11775-11783	purified	_
83-17	11784-11795	PCR-product	_
83-18	11796-11797	,	_
83-19	11798-11799	5	_
83-20	11800-11801	U	_
83-21	11802-11806	HhaI	_
83-22	11807-11808	,	_
83-23	11809-11811	1×	_
83-24	11812-11820	NEBuffer	_
83-25	11821-11822	4	_
83-26	11823-11826	and	_
83-27	11827-11829	1×	_
83-28	11830-11833	BSA	_
83-29	11834-11835	.	_

84-1	11836-11845	Digestion	_
84-2	11846-11849	was	_
84-3	11850-11859	performed	_
84-4	11860-11862	at	_
84-5	11863-11865	37	_
84-6	11866-11868	°C	_
84-7	11869-11872	for	_
84-8	11873-11875	16	_
84-9	11876-11877	h	_
84-10	11878-11879	,	_
84-11	11880-11885	which	_
84-12	11886-11894	resulted	_
84-13	11895-11897	in	_
84-14	11898-11901	two	_
84-15	11902-11911	fragments	_
84-16	11912-11914	of	_
84-17	11915-11918	200	_
84-18	11919-11921	bp	_
84-19	11922-11925	and	_
84-20	11926-11928	24	_
84-21	11929-11931	bp	_
84-22	11932-11935	for	_
84-23	11936-11939	the	_
84-24	11940-11941	C	_
84-25	11942-11948	allele	_
84-26	11949-11950	,	_
84-27	11951-11954	the	_
84-28	11955-11956	T	_
84-29	11957-11964	variant	_
84-30	11965-11973	remained	_
84-31	11974-11979	uncut	_
84-32	11980-11981	(	_
84-33	11982-11985	224	_
84-34	11986-11988	bp	_
84-35	11989-11990	)	_
84-36	11991-11992	.	_

85-1	11993-12003	Statistics	_
85-2	12004-12005	A	_
85-3	12006-12011	total	_
85-4	12012-12014	of	_
85-5	12015-12018	122	_
85-6	12019-12031	participants	_
85-7	12032-12039	entered	_
85-8	12040-12043	the	_
85-9	12044-12049	study	_
85-10	12050-12051	.	_

86-1	12052-12055	DBH	_
86-2	12056-12064	genotype	_
86-3	12065-12069	data	_
86-4	12070-12073	was	_
86-5	12074-12081	missing	_
86-6	12082-12084	in	_
86-7	12085-12086	6	_
86-8	12087-12099	participants	_
86-9	12100-12103	and	_
86-10	12104-12108	MFFT	_
86-11	12109-12117	datasets	_
86-12	12118-12120	of	_
86-13	12121-12128	another	_
86-14	12129-12130	6	_
86-15	12131-12143	participants	_
86-16	12144-12148	were	_
86-17	12149-12159	incomplete	_
86-18	12160-12161	,	_
86-19	12162-12165	due	_
86-20	12166-12168	to	_
86-21	12169-12178	technical	_
86-22	12179-12187	failures	_
86-23	12188-12189	.	_

87-1	12190-12202	Consequently	_
87-2	12203-12204	,	_
87-3	12205-12208	110	_
87-4	12209-12221	participants	_
87-5	12222-12226	with	_
87-6	12227-12235	complete	_
87-7	12236-12244	datasets	_
87-8	12245-12252	entered	_
87-9	12253-12256	the	_
87-10	12257-12268	statistical	_
87-11	12269-12277	analyses	_
87-12	12278-12280	of	_
87-13	12281-12285	MFFT	_
87-14	12286-12290	data	_
87-15	12291-12292	.	_

88-1	12293-12296	For	_
88-2	12297-12305	analysis	_
88-3	12306-12307	,	_
88-4	12308-12319	individuals	_
88-5	12320-12324	with	_
88-6	12325-12328	low	_
88-7	12329-12337	activity	_
88-8	12338-12341	DBH	_
88-9	12342-12351	genotypes	_
88-10	12352-12353	,	_
88-11	12354-12357	i.e	_
88-12	12358-12359	.	_

89-1	12360-12362	CT	_
89-2	12363-12364	(	_
89-3	12365-12366	N	_
89-4	12367-12368	=	_
89-5	12369-12371	33	_
89-6	12372-12373	)	_
89-7	12374-12377	and	_
89-8	12378-12380	TT	_
89-9	12381-12382	(	_
89-10	12383-12384	N	_
89-11	12385-12386	=	_
89-12	12387-12388	4	_
89-13	12389-12390	)	_
89-14	12391-12392	,	_
89-15	12393-12397	were	_
89-16	12398-12404	pooled	_
89-17	12405-12406	(	_
89-18	12407-12412	CT/TT	_
89-19	12413-12414	)	_
89-20	12415-12418	and	_
89-21	12419-12427	compared	_
89-22	12428-12430	to	_
89-23	12431-12433	CC	_
89-24	12434-12445	homozygotes	_
89-25	12446-12447	(	_
89-26	12448-12449	N	_
89-27	12450-12451	=	_
89-28	12452-12454	73	_
89-29	12455-12456	)	_
89-30	12457-12458	.	_

90-1	12459-12460	A	_
90-2	12461-12466	total	_
90-3	12467-12469	of	_
90-4	12470-12472	61	_
90-5	12473-12485	participants	_
90-6	12486-12487	(	_
90-7	12488-12491	the	_
90-8	12492-12502	Maastricht	_
90-9	12503-12509	sample	_
90-10	12510-12511	)	_
90-11	12512-12524	participated	_
90-12	12525-12527	in	_
90-13	12528-12535	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
90-14	12536-12541	state	_
90-15	12542-12550	measures	_
90-16	12551-12552	.	_

91-1	12553-12557	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
91-2	12558-12566	datasets	_
91-3	12567-12571	were	_
91-4	12572-12582	incomplete	_
91-5	12583-12586	for	_
91-6	12587-12589	22	_
91-7	12590-12602	participants	_
91-8	12603-12606	due	_
91-9	12607-12609	to	_
91-10	12610-12619	technical	_
91-11	12620-12628	failures	_
91-12	12629-12631	or	_
91-13	12632-12635	due	_
91-14	12636-12638	to	_
91-15	12639-12648	excessive	_
91-16	12649-12657	movement	_
91-17	12658-12664	during	_
91-18	12665-12669	drug	_
91-19	12670-12680	conditions	_
91-20	12681-12682	,	_
91-21	12683-12692	rendering	_
91-22	12693-12695	39	_
91-23	12696-12708	participants	_
91-24	12709-12713	with	_
91-25	12714-12722	complete	_
91-26	12723-12727	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
91-27	12728-12736	datasets	_
91-28	12737-12738	.	_

92-1	12739-12742	DBH	_
92-2	12743-12751	genotype	_
92-3	12752-12755	was	_
92-4	12756-12763	missing	_
92-5	12764-12766	in	_
92-6	12767-12768	4	_
92-7	12769-12771	of	_
92-8	12772-12777	those	_
92-9	12778-12790	participants	_
92-10	12791-12792	,	_
92-11	12793-12798	which	_
92-12	12799-12807	rendered	_
92-13	12808-12810	35	_
92-14	12811-12823	participants	_
92-15	12824-12828	with	_
92-16	12829-12837	complete	_
92-17	12838-12846	datasets	_
92-18	12847-12849	to	_
92-19	12850-12854	test	_
92-20	12855-12858	for	_
92-21	12859-12863	Drug	_
92-22	12864-12865	x	_
92-23	12866-12869	DBH	_
92-24	12870-12882	interactions	_
92-25	12883-12885	on	_
92-26	12886-12896	functional	_
92-27	12897-12909	connectivity	_
92-28	12910-12911	.	_

93-1	12912-12919	Effects	_
93-2	12920-12922	on	_
93-3	12923-12930	impulse	_
93-4	12931-12938	control	_
93-5	12939-12944	tasks	_
93-6	12945-12949	from	_
93-7	12950-12954	oral	_
93-8	12955-12958	THC	http://maven.renci.org/NeuroBridge/neurobridge#DeathCertificate
93-9	12959-12962	and	_
93-10	12963-12970	cocaine	_
93-11	12971-12974	HCl	_
93-12	12975-12977	in	_
93-13	12978-12985	dosages	_
93-14	12986-12993	similar	_
93-15	12994-12996	to	_
93-16	12997-13002	those	_
93-17	13003-13011	proposed	_
93-18	13012-13015	for	_
93-19	13016-13020	this	_
93-20	13021-13026	study	_
93-21	13027-13031	have	_
93-22	13032-13040	achieved	_
93-23	13041-13052	statistical	_
93-24	13053-13065	significance	_
93-25	13066-13068	in	_
93-26	13069-13075	within	_
93-27	13076-13083	subject	_
93-28	13084-13091	designs	_
93-29	13092-13101	employing	_
93-30	13102-13104	20	_
93-31	13105-13107	or	_
93-32	13108-13112	less	_
93-33	13113-13125	participants	_
93-34	13126-13127	(	_
93-35	13128-13136	Fillmore	_
93-36	13137-13139	et	_
93-37	13140-13142	al	_
93-38	13143-13144	.	_

94-1	13145-13146	;	_
94-2	13147-13156	Ramaekers	_
94-3	13157-13159	et	_
94-4	13160-13162	al	_
94-5	13163-13164	.	_

95-1	13165-13166	;	_
95-2	13167-13176	Ramaekers	_
95-3	13177-13180	and	_
95-4	13181-13188	Kuypers	_
95-5	13189-13190	)	_
95-6	13191-13192	.	_

96-1	13193-13201	Assuming	_
96-2	13202-13204	an	_
96-3	13205-13212	omnibus	_
96-4	13213-13214	p	_
96-5	13215-13216	<	_
96-6	13217-13221	0.05	_
96-7	13222-13225	and	_
96-8	13226-13231	power	_
96-9	13232-13233	=	_
96-10	13234-13237	0.8	_
96-11	13238-13239	,	_
96-12	13240-13242	we	_
96-13	13243-13252	estimated	_
96-14	13253-13257	that	_
96-15	13258-13261	the	_
96-16	13262-13269	present	_
96-17	13270-13275	study	_
96-18	13276-13285	employing	_
96-19	13286-13289	122	_
96-20	13290-13298	subjects	_
96-21	13299-13304	would	_
96-22	13305-13311	enable	_
96-23	13312-13321	detection	_
96-24	13322-13324	of	_
96-25	13325-13336	performance	_
96-26	13337-13348	differences	_
96-27	13349-13356	between	_
96-28	13357-13361	drug	_
96-29	13362-13372	treatments	_
96-30	13373-13377	with	_
96-31	13378-13380	an	_
96-32	13381-13387	effect	_
96-33	13388-13392	size	_
96-34	13393-13395	of	_
96-35	13396-13399	0.3	_
96-36	13400-13401	(	_
96-37	13402-13406	i.e.	_
96-38	13407-13408	,	_
96-39	13409-13410	a	_
96-40	13411-13417	signal	_
96-41	13418-13424	change	_
96-42	13425-13427	of	_
96-43	13428-13430	.3	_
96-44	13431-13436	times	_
96-45	13437-13440	the	_
96-46	13441-13449	standard	_
96-47	13450-13459	deviation	_
96-48	13460-13461	)	_
96-49	13462-13464	in	_
96-50	13465-13471	within	_
96-51	13472-13479	subject	_
96-52	13480-13491	comparisons	_
96-53	13492-13493	.	_

97-1	13494-13496	In	_
97-2	13497-13505	addition	_
97-3	13506-13507	,	_
97-4	13508-13510	we	_
97-5	13511-13520	estimated	_
97-6	13521-13525	that	_
97-7	13526-13533	between	_
97-8	13534-13537	DBH	_
97-9	13538-13543	group	_
97-10	13544-13555	comparisons	_
97-11	13556-13558	of	_
97-12	13559-13568	genotypes	_
97-13	13569-13574	would	_
97-14	13575-13581	enable	_
97-15	13582-13591	detection	_
97-16	13592-13594	of	_
97-17	13595-13606	performance	_
97-18	13607-13618	differences	_
97-19	13619-13623	with	_
97-20	13624-13626	an	_
97-21	13627-13633	effect	_
97-22	13634-13638	size	_
97-23	13639-13641	of	_
97-24	13642-13644	.7	_
97-25	13645-13648	and	_
97-26	13649-13651	.4	_
97-27	13652-13655	for	_
97-28	13656-13661	sizes	_
97-29	13662-13664	of	_
97-30	13665-13666	N	_
97-31	13667-13668	=	_
97-32	13669-13671	30	_
97-33	13672-13675	and	_
97-34	13676-13677	N	_
97-35	13678-13679	=	_
97-36	13680-13682	60	_
97-37	13683-13695	respectively	_
97-38	13696-13697	.	_

98-1	13698-13713	Straightforward	_
98-2	13714-13719	power	_
98-3	13720-13728	analysis	_
98-4	13729-13732	for	_
98-5	13733-13740	imaging	_
98-6	13741-13745	data	_
98-7	13746-13748	is	_
98-8	13749-13753	less	_
98-9	13754-13762	feasible	_
98-10	13763-13764	.	_

99-1	13765-13772	Because	_
99-2	13773-13777	fMRI	_
99-3	13778-13782	data	_
99-4	13783-13791	analysis	_
99-5	13792-13800	consists	_
99-6	13801-13803	of	_
99-7	13804-13805	a	_
99-8	13806-13810	very	_
99-9	13811-13816	large	_
99-10	13817-13823	number	_
99-11	13824-13826	of	_
99-12	13827-13842	non-independent	_
99-13	13843-13851	multiple	_
99-14	13852-13863	comparisons	_
99-15	13864-13865	,	_
99-16	13866-13867	a	_
99-17	13868-13874	proper	_
99-18	13875-13880	power	_
99-19	13881-13889	analysis	_
99-20	13890-13894	with	_
99-21	13895-13905	correction	_
99-22	13906-13909	for	_
99-23	13910-13918	multiple	_
99-24	13919-13930	comparisons	_
99-25	13931-13939	requires	_
99-26	13940-13948	computer	_
99-27	13949-13959	simulation	_
99-28	13960-13961	.	_

100-1	13962-13964	In	_
100-2	13965-13973	addition	_
100-3	13974-13975	,	_
100-4	13976-13987	statistical	_
100-5	13988-13993	power	_
100-6	13994-13996	is	_
100-7	13997-14000	not	_
100-8	14001-14004	the	_
100-9	14005-14009	same	_
100-10	14010-14011	(	_
100-11	14012-14016	i.e.	_
100-12	14017-14018	,	_
100-13	14019-14029	homogenous	_
100-14	14030-14031	)	_
100-15	14032-14036	over	_
100-16	14037-14040	the	_
100-17	14041-14046	brain	_
100-18	14047-14048	,	_
100-19	14049-14052	but	_
100-20	14053-14059	varies	_
100-21	14060-14066	across	_
100-22	14067-14072	brain	_
100-23	14073-14080	regions	_
100-24	14081-14082	(	_
100-25	14083-14092	Petersson	_
100-26	14093-14095	et	_
100-27	14096-14098	al	_
100-28	14099-14100	.	_
100-29	14101-14102	)	_
100-30	14103-14104	.	_

101-1	14105-14106	A	_
101-2	14107-14113	common	_
101-3	14114-14122	approach	_
101-4	14123-14125	in	_
101-5	14126-14129	the	_
101-6	14130-14140	functional	_
101-7	14141-14153	neuroimaging	_
101-8	14154-14163	community	_
101-9	14164-14166	is	_
101-10	14167-14169	to	_
101-11	14170-14178	estimate	_
101-12	14179-14182	the	_
101-13	14183-14189	number	_
101-14	14190-14192	of	_
101-15	14193-14201	subjects	_
101-16	14202-14206	from	_
101-17	14207-14215	previous	_
101-18	14216-14225	empirical	_
101-19	14226-14236	experience	_
101-20	14237-14239	in	_
101-21	14240-14243	the	_
101-22	14244-14249	field	_
101-23	14250-14251	,	_
101-24	14252-14264	particularly	_
101-25	14265-14269	when	_
101-26	14270-14275	pilot	_
101-27	14276-14280	data	_
101-28	14281-14284	are	_
101-29	14285-14292	lacking	_
101-30	14293-14296	and	_
101-31	14297-14305	analyses	_
101-32	14306-14313	include	_
101-33	14314-14317	the	_
101-34	14318-14323	whole	_
101-35	14324-14329	brain	_
101-36	14330-14332	or	_
101-37	14333-14341	multiple	_
101-38	14342-14349	regions	_
101-39	14350-14352	of	_
101-40	14353-14361	interest	_
101-41	14362-14363	(	_
101-42	14364-14371	Mumford	_
101-43	14372-14373	)	_
101-44	14374-14375	.	_

102-1	14376-14384	Previous	_
102-2	14385-14392	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
102-3	14393-14398	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
102-4	14399-14403	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
102-5	14404-14411	studies	_
102-6	14412-14416	have	_
102-7	14417-14425	employed	_
102-8	14426-14431	15–20	_
102-9	14432-14440	subjects	_
102-10	14441-14444	for	_
102-11	14445-14452	showing	_
102-12	14453-14464	significant	_
102-13	14465-14469	drug	_
102-14	14470-14477	effects	_
102-15	14478-14479	(	_
102-16	14480-14485	Honey	_
102-17	14486-14488	et	_
102-18	14489-14491	al	_
102-19	14492-14493	.	_

103-1	14494-14495	;	_
103-2	14496-14501	Kelly	_
103-3	14502-14504	et	_
103-4	14505-14507	al	_
103-5	14508-14509	.	_

104-1	14510-14511	;	_
104-2	14512-14521	Ramaekers	_
104-3	14522-14524	et	_
104-4	14525-14527	al	_
104-5	14528-14529	.	_

105-1	14530-14531	;	_
105-2	14532-14541	Schrantee	_
105-3	14542-14544	et	_
105-4	14545-14547	al	_
105-5	14548-14549	.	_
105-6	14550-14551	)	_
105-7	14552-14553	.	_

106-1	14554-14559	Based	_
106-2	14560-14562	on	_
106-3	14563-14568	these	_
106-4	14569-14580	experiences	_
106-5	14581-14583	we	_
106-6	14584-14592	expected	_
106-7	14593-14595	no	_
106-8	14596-14603	problem	_
106-9	14604-14606	to	_
106-10	14607-14618	demonstrate	_
106-11	14619-14623	drug	_
106-12	14624-14631	effects	_
106-13	14632-14634	on	_
106-14	14635-14639	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
106-15	14640-14648	measures	_
106-16	14649-14651	in	_
106-17	14652-14654	60	_
106-18	14655-14667	participants	_
106-19	14668-14671	and	_
106-20	14672-14676	that	_
106-21	14677-14683	sample	_
106-22	14684-14689	sizes	_
106-23	14690-14692	of	_
106-24	14693-14702	subgroups	_
106-25	14703-14706	DBH	_
106-26	14707-14716	genotypes	_
106-27	14717-14718	(	_
106-28	14719-14720	N	_
106-29	14721-14722	=	_
106-30	14723-14728	15–30	_
106-31	14729-14730	)	_
106-32	14731-14736	would	_
106-33	14737-14739	be	_
106-34	14740-14750	sufficient	_
106-35	14751-14754	for	_
106-36	14755-14768	demonstrating	_
106-37	14769-14776	between	_
106-38	14777-14782	group	_
106-39	14783-14794	differences	_
106-40	14795-14796	.	_

107-1	14797-14801	MFFT	_
107-2	14802-14810	measures	_
107-3	14811-14815	were	_
107-4	14816-14824	analyzed	_
107-5	14825-14829	with	_
107-6	14830-14834	SPSS	_
107-7	14835-14839	21.0	_
107-8	14840-14845	using	_
107-9	14846-14847	a	_
107-10	14848-14851	GLM	_
107-11	14852-14862	univariate	_
107-12	14863-14871	analysis	_
107-13	14872-14874	of	_
107-14	14875-14883	variance	_
107-15	14884-14885	(	_
107-16	14886-14891	ANOVA	_
107-17	14892-14893	)	_
107-18	14894-14898	with	_
107-19	14899-14903	Drug	_
107-20	14904-14905	(	_
107-21	14906-14907	3	_
107-22	14908-14914	levels	_
107-23	14915-14916	;	_
107-24	14917-14924	placebo	_
107-25	14925-14926	,	_
107-26	14927-14935	cannabis	_
107-27	14936-14939	and	_
107-28	14940-14947	cocaine	_
107-29	14948-14949	)	_
107-30	14950-14952	as	_
107-31	14953-14959	within	_
107-32	14960-14967	subject	_
107-33	14968-14974	factor	_
107-34	14975-14978	and	_
107-35	14979-14982	DBH	_
107-36	14983-14991	genotype	_
107-37	14992-14993	(	_
107-38	14994-14995	2	_
107-39	14996-15002	levels	_
107-40	15003-15004	;	_
107-41	15005-15007	CC	_
107-42	15008-15011	and	_
107-43	15012-15017	CT/TT	_
107-44	15018-15019	)	_
107-45	15020-15022	as	_
107-46	15023-15030	between	_
107-47	15031-15036	group	_
107-48	15037-15043	factor	_
107-49	15044-15045	.	_

108-1	15046-15049	The	_
108-2	15050-15055	model	_
108-3	15056-15062	tested	_
108-4	15063-15066	for	_
108-5	15067-15071	main	_
108-6	15072-15079	effects	_
108-7	15080-15082	of	_
108-8	15083-15087	Drug	_
108-9	15088-15089	,	_
108-10	15090-15093	DBH	_
108-11	15094-15102	genotype	_
108-12	15103-15106	and	_
108-13	15107-15112	their	_
108-14	15113-15124	interaction	_
108-15	15125-15126	.	_

109-1	15127-15138	Significant	_
109-2	15139-15143	main	_
109-3	15144-15151	effects	_
109-4	15152-15156	were	_
109-5	15157-15169	subsequently	_
109-6	15170-15178	followed	_
109-7	15179-15181	by	_
109-8	15182-15194	drug-placebo	_
109-9	15195-15204	contrasts	_
109-10	15205-15207	to	_
109-11	15208-15217	establish	_
109-12	15218-15221	the	_
109-13	15222-15230	separate	_
109-14	15231-15238	effects	_
109-15	15239-15241	of	_
109-16	15242-15250	cannabis	_
109-17	15251-15252	(	_
109-18	15253-15254	2	_
109-19	15255-15261	within	_
109-20	15262-15269	subject	_
109-21	15270-15276	levels	_
109-22	15277-15278	;	_
109-23	15279-15286	placebo	_
109-24	15287-15290	and	_
109-25	15291-15299	cannabis	_
109-26	15300-15301	)	_
109-27	15302-15305	and	_
109-28	15306-15313	cocaine	_
109-29	15314-15315	(	_
109-30	15316-15317	2	_
109-31	15318-15324	within	_
109-32	15325-15332	subject	_
109-33	15333-15339	levels	_
109-34	15340-15341	;	_
109-35	15342-15349	placebo	_
109-36	15350-15353	and	_
109-37	15354-15361	cocaine	_
109-38	15362-15363	)	_
109-39	15364-15367	and	_
109-40	15368-15373	their	_
109-41	15374-15385	interaction	_
109-42	15386-15390	with	_
109-43	15391-15394	DBH	_
109-44	15395-15403	genotype	_
109-45	15404-15405	(	_
109-46	15406-15407	2	_
109-47	15408-15415	between	_
109-48	15416-15421	group	_
109-49	15422-15428	levels	_
109-50	15429-15430	;	_
109-51	15431-15433	CC	_
109-52	15434-15437	and	_
109-53	15438-15443	CT/TT	_
109-54	15444-15445	)	_
109-55	15446-15447	.	_

110-1	15448-15458	Functional	_
110-2	15459-15471	connectivity	_
110-3	15472-15476	data	_
110-4	15477-15478	(	_
110-5	15479-15482	i.e	_
110-6	15483-15484	.	_

111-1	15485-15496	correlation	_
111-2	15497-15508	coefficient	_
111-3	15509-15513	maps	_
111-4	15514-15517	for	_
111-5	15518-15522	each	_
111-6	15523-15533	individual	_
111-7	15534-15536	in	_
111-8	15537-15541	each	_
111-9	15542-15551	treatment	_
111-10	15552-15561	condition	_
111-11	15562-15563	)	_
111-12	15564-15568	were	_
111-13	15569-15577	analysed	_
111-14	15578-15580	in	_
111-15	15581-15582	2	_
111-16	15583-15586	GLM	_
111-17	15587-15593	models	_
111-18	15594-15596	of	_
111-19	15597-15602	ANOVA	_
111-20	15603-15605	in	_
111-21	15606-15610	SPM8	_
111-22	15611-15612	.	_

112-1	15613-15615	In	_
112-2	15616-15619	the	_
112-3	15620-15625	first	_
112-4	15626-15629	GLM	_
112-5	15630-15631	,	_
112-6	15632-15640	complete	_
112-7	15641-15649	datasets	_
112-8	15650-15652	of	_
112-9	15653-15655	39	_
112-10	15656-15668	participants	_
112-11	15669-15673	were	_
112-12	15674-15682	analysed	_
112-13	15683-15688	using	_
112-14	15689-15694	ANOVA	_
112-15	15695-15699	with	_
112-16	15700-15704	Drug	_
112-17	15705-15706	(	_
112-18	15707-15708	3	_
112-19	15709-15715	levels	_
112-20	15716-15717	)	_
112-21	15718-15720	as	_
112-22	15721-15727	within	_
112-23	15728-15735	subject	_
112-24	15736-15742	factor	_
112-25	15743-15744	.	_

113-1	15745-15748	The	_
113-2	15749-15752	GLM	_
113-3	15753-15758	model	_
113-4	15759-15770	established	_
113-5	15771-15774	the	_
113-6	15775-15782	effects	_
113-7	15783-15785	of	_
113-8	15786-15794	cannabis	_
113-9	15795-15798	and	_
113-10	15799-15806	cocaine	_
113-11	15807-15817	separately	_
113-12	15818-15820	by	_
113-13	15821-15826	means	_
113-14	15827-15829	of	_
113-15	15830-15842	drug-placebo	_
113-16	15843-15852	contrasts	_
113-17	15853-15854	.	_

114-1	15855-15858	DBH	_
114-2	15859-15869	genotyping	_
114-3	15870-15873	was	_
114-4	15874-15878	only	_
114-5	15879-15888	available	_
114-6	15889-15892	for	_
114-7	15893-15895	35	_
114-8	15896-15908	participants	_
114-9	15909-15910	(	_
114-10	15911-15913	CC	_
114-11	15914-15922	genotype	_
114-12	15923-15924	N	_
114-13	15925-15926	=	_
114-14	15927-15929	22	_
114-15	15930-15931	;	_
114-16	15932-15937	CT/TT	_
114-17	15938-15946	genotype	_
114-18	15947-15948	N	_
114-19	15949-15950	=	_
114-20	15951-15953	13	_
114-21	15954-15955	)	_
114-22	15956-15960	that	_
114-23	15961-15965	were	_
114-24	15966-15974	included	_
114-25	15975-15977	in	_
114-26	15978-15981	GLM	_
114-27	15982-15983	1	_
114-28	15984-15985	.	_

115-1	15986-15995	Therefore	_
115-2	15996-15997	a	_
115-3	15998-16001	2nd	_
115-4	16002-16005	GLM	_
115-5	16006-16009	was	_
115-6	16010-16019	conducted	_
115-7	16020-16024	that	_
115-8	16025-16033	included	_
115-9	16034-16036	35	_
115-10	16037-16049	participants	_
115-11	16050-16053	for	_
115-12	16054-16059	which	_
115-13	16060-16064	both	_
115-14	16065-16072	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
115-15	16073-16078	state	_
115-16	16079-16082	and	_
115-17	16083-16086	DBH	_
115-18	16087-16091	data	_
115-19	16092-16096	sets	_
115-20	16097-16101	were	_
115-21	16102-16110	complete	_
115-22	16111-16112	.	_

116-1	16113-16118	These	_
116-2	16119-16123	data	_
116-3	16124-16128	were	_
116-4	16129-16136	entered	_
116-5	16137-16139	in	_
116-6	16140-16142	an	_
116-7	16143-16148	ANOVA	_
116-8	16149-16153	with	_
116-9	16154-16158	Drug	_
116-10	16159-16160	(	_
116-11	16161-16162	3	_
116-12	16163-16169	levels	_
116-13	16170-16171	)	_
116-14	16172-16174	as	_
116-15	16175-16181	within	_
116-16	16182-16189	subject	_
116-17	16190-16196	factor	_
116-18	16197-16200	and	_
116-19	16201-16204	DBH	_
116-20	16205-16213	genotype	_
116-21	16214-16215	(	_
116-22	16216-16217	2	_
116-23	16218-16224	levels	_
116-24	16225-16226	)	_
116-25	16227-16229	as	_
116-26	16230-16237	between	_
116-27	16238-16243	group	_
116-28	16244-16250	factor	_
116-29	16251-16252	.	_

117-1	16253-16257	From	_
117-2	16258-16262	this	_
117-3	16263-16268	model	_
117-4	16269-16270	,	_
117-5	16271-16275	main	_
117-6	16276-16283	effects	_
117-7	16284-16286	of	_
117-8	16287-16290	DBH	_
117-9	16291-16299	genotype	_
117-10	16300-16303	and	_
117-11	16304-16307	its	_
117-12	16308-16319	interaction	_
117-13	16320-16324	with	_
117-14	16325-16333	cannabis	_
117-15	16334-16337	and	_
117-16	16338-16345	cocaine	_
117-17	16346-16355	treatment	_
117-18	16356-16360	were	_
117-19	16361-16371	identified	_
117-20	16372-16373	.	_

118-1	16374-16377	The	_
118-2	16378-16389	statistical	_
118-3	16390-16399	threshold	_
118-4	16400-16403	was	_
118-5	16404-16407	set	_
118-6	16408-16410	at	_
118-7	16411-16412	p	_
118-8	16413-16414	<	_
118-9	16415-16418	.05	_
118-10	16419-16422	FWE	_
118-11	16423-16430	cluster	_
118-12	16431-16440	corrected	_
118-13	16441-16442	(	_
118-14	16443-16450	cluster	_
118-15	16451-16455	size	_
118-16	16456-16457	>	_
118-17	16458-16460	50	_
118-18	16461-16462	)	_
118-19	16463-16464	.	_

119-1	16465-16472	Finally	_
119-2	16473-16474	,	_
119-3	16475-16480	voxel	_
119-4	16481-16485	wise	_
119-5	16486-16497	correlation	_
119-6	16498-16506	analysis	_
119-7	16507-16514	between	_
119-8	16515-16517	FC	_
119-9	16518-16522	data	_
119-10	16523-16526	and	_
119-11	16527-16531	MFFT	_
119-12	16532-16541	composite	_
119-13	16542-16550	measures	_
119-14	16551-16553	of	_
119-15	16554-16565	Impulsivity	_
119-16	16566-16569	and	_
119-17	16570-16580	Efficiency	_
119-18	16581-16585	were	_
119-19	16586-16595	conducted	_
119-20	16596-16597	.	_

